The	O
small	B-protein
GTP-binding	I-protein
protein	I-protein
Rho	I-protein
potentiates	O
AP-1	B-protein
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
Rho	B-protein
family	O
of	O
small	B-protein
GTP-binding	I-protein
proteins	I-protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
cytoskeletal	O
structure	O
,	O
gene	O
transcription	O
,	O
specific	O
cell	O
fate	O
development	O
,	O
and	O
transformation	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
overexpression	O
of	O
an	O
activated	O
form	O
of	O
Rho	B-protein
enhances	O
AP-1	B-protein
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
the	O
presence	O
of	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
but	O
activated	O
Rho	B-protein
(	O
V14Rho	B-protein
)	O
has	O
little	O
or	O
no	O
effect	O
on	O
NFAT	B-protein
,	O
Oct-1	B-protein
,	O
and	O
NF-kappaB	B-DNA
enhancer	I-DNA
element	I-DNA
activities	O
under	O
similar	O
conditions	O
.	O

Overexpression	O
of	O
a	O
V14Rho	B-DNA
construct	I-DNA
incapable	O
of	O
membrane	O
localization	O
(	O
CAAX	B-DNA
deleted	I-DNA
)	O
abolishes	O
PMA-induced	O
AP-1	B-protein
transcriptional	O
activation	O
.	O

The	O
effect	O
of	O
Rho	B-protein
on	O
AP-1	B-protein
is	O
independent	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathway	O
,	O
as	O
a	O
dominant-negative	B-protein
MEK	I-protein
and	O
a	O
MEK	B-protein
inhibitor	O
(	O
PD98059	O
)	O
did	O
not	O
affect	O
Rho	B-protein
-induced	O
AP-1	B-protein
activity	O
.	O

V14Rho	B-protein
binds	O
strongly	O
to	O
protein	B-protein
kinase	I-protein
Calpha	I-protein
(	O
PKCalpha	B-protein
)	O
in	O
vivo	O
;	O
however	O
,	O
deletion	O
of	O
the	O
CAAX	B-DNA
site	I-DNA
on	O
V14Rho	B-protein
severely	O
diminished	O
this	O
association	O
.	O

Evidence	O
for	O
a	O
role	O
for	O
PKCalpha	B-protein
as	O
an	O
effector	O
of	O
Rho	B-protein
was	O
obtained	O
by	O
the	O
observation	O
that	O
coexpression	O
of	O
the	O
N-terminal	B-protein
domain	I-protein
of	O
PKCalpha	B-protein
blocked	O
the	O
effects	O
of	O
activated	O
Rho	B-protein
plus	O
PMA	O
on	O
AP-1	B-protein
transcriptional	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
Rho	B-protein
potentiates	O
AP-1	B-protein
transcription	O
during	O
T-cell	O
activation	O

MoLECULAR	NULL
AND	NULL
CELLULAR	NULL
BIOLOGY	NULL
,	NULL
Sept.	NULL
1998	NULL
,	NULL
p.	NULL
4986-4993	NULL
0270-7306/98/	NULL
$	NULL
04.00+0	NULL
Vol	NULL
.	NULL

18	NULL
,	NULL
No	NULL
.	NULL

9	NULL
Copyright	NULL
©	NULL
1998	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

The	NULL
Small	NULL
GTP-Binding	NULL
Protein	NULL
Rho	NULL
Potentiates	NULL
AP-1	NULL
Transcription	NULL
in	NULL
T	NULL
Cells	NULL
JIN-HONG	NULL
CHANG	NULL
,	NULL
JOANNE	NULL
C.	NULL
PRATT	NULL
,	NULL
SANSANA	NULL
SAWASDIKOSOL	NULL
,	NULL
ROSANA	NULL
KAPELLER	NULL
,	NULL
Anp	NULL
STEVEN	NULL
J.	NULL
BURAKOFF*	NULL
Division	NULL
of	NULL
Pediatric	NULL
Oncology	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Pediatrics	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
Received	NULL
1	NULL
December	NULL
1997/Returned	NULL
for	NULL
modification	NULL
30	NULL
December	NULL
1997/Accepted	NULL
29	NULL
May	NULL
1998	NULL
The	NULL
Rho	NULL
family	NULL
of	NULL
small	NULL
GTP-binding	NULL
proteins	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
cytoskeletal	NULL
structure	NULL
,	NULL
gene	NULL
transcription	NULL
,	NULL
specific	NULL
cell	NULL
fate	NULL
development	NULL
,	NULL
and	NULL
transformation	NULL
.	NULL

We	NULL
demonstrate	NULL
in	NULL
this	NULL
report	NULL
that	NULL
overexpression	NULL
of	NULL
an	NULL
activated	NULL
form	NULL
of	NULL
Rho	NULL
enhances	NULL
AP-1	NULL
activity	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
but	NULL
activated	NULL
Rho	NULL
(	NULL
V14Rho	NULL
)	NULL
has	NULL
little	NULL
or	NULL
no	NULL
effect	NULL
on	NULL
NFAT	NULL
,	NULL
Oct-1	NULL
,	NULL
and	NULL
NF-KB	NULL
enhancer	NULL
element	NULL
activities	NULL
under	NULL
similar	NULL
conditions	NULL
.	NULL

Overexpression	NULL
of	NULL
a	NULL
V14Rho	NULL
construct	NULL
incapable	NULL
of	NULL
membrane	NULL
localization	NULL
(	NULL
CAAX	NULL
deleted	NULL
)	NULL
abolishes	NULL
PMA-induced	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
Rho	NULL
on	NULL
AP-1	NULL
is	NULL
independent	NULL
of	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
pathway	NULL
,	NULL
as	NULL
a	NULL
dominant-negative	NULL
MEK	NULL
and	NULL
a	NULL
MEK	NULL
inhibitor	NULL
(	NULL
PD98059	NULL
)	NULL
did	NULL
not	NULL
affect	NULL
Rho-induced	NULL
AP-1	NULL
activity	NULL
.	NULL

V14Rho	NULL
binds	NULL
strongly	NULL
to	NULL
protein	NULL
kinase	NULL
Ca	NULL
(	NULL
PKCa	NULL
)	NULL
in	NULL
vivo	NULL
;	NULL
however	NULL
,	NULL
deletion	NULL
of	NULL
the	NULL
CAAX	NULL
site	NULL
on	NULL
V14Rho	NULL
severely	NULL
diminished	NULL
this	NULL
association	NULL
.	NULL

Evidence	NULL
for	NULL
a	NULL
role	NULL
for	NULL
PKCa	NULL
as	NULL
an	NULL
effector	NULL
of	NULL
Rho	NULL
was	NULL
obtained	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
coexpression	NULL
of	NULL
the	NULL
N-terminal	NULL
domain	NULL
of	NULL
PKCa	NULL
blocked	NULL
the	NULL
effects	NULL
of	NULL
activated	NULL
Rho	NULL
plus	NULL
PMA	NULL
on	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
Rho	NULL
potentiates	NULL
AP-1	NULL
transcription	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
Ras-related	NULL
Rho	NULL
family	NULL
members	NULL
are	NULL
involved	NULL
in	NULL
thymic	NULL
development	NULL
,	NULL
cell	NULL
transformation	NULL
,	NULL
actin	NULL
cytoskeletal	NULL
rearrange-ment	NULL
,	NULL
and	NULL
cell	NULL
polarity	NULL
(	NULL
17	NULL
,	NULL
26	NULL
,	NULL
35	NULL
,	NULL
36	NULL
,	NULL
41	NULL
,	NULL
47	NULL
)	NULL
.	NULL

The	NULL
Rho	NULL
family	NULL
is	NULL
comprised	NULL
of	NULL
several	NULL
related	NULL
proteins	NULL
,	NULL
including	NULL
Racl	NULL
,	NULL
RacZ	NULL
,	NULL
RhoA	NULL
,	NULL
RhoB	NULL
,	NULL
RhoC	NULL
,	NULL
Cde42Hs	NULL
,	NULL
and	NULL
TC1O	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
,	NULL
which	NULL
share	NULL
structural	NULL
similarity	NULL
with	NULL
Ras	NULL
.	NULL

These	NULL
proteins	NULL
contain	NULL
intrinsic	NULL
GTPase	NULL
activity	NULL
and	NULL
bind	NULL
GTP	NULL
and	NULL
GDP	NULL
in	NULL
a	NULL
manner	NULL
that	NULL
is	NULL
regulated	NULL
by	NULL
guanine	NULL
nucleotide	NULL
exchange	NULL
factors	NULL
(	NULL
GEFs	NULL
)	NULL
,	NULL
GTPase-activating	NULL
proteins	NULL
(	NULL
GAPs	NULL
)	NULL
,	NULL
and	NULL
guanine	NULL
nucleotide	NULL
dissociation	NULL
inhibitors	NULL
(	NULL
GDIs	NULL
)	NULL
(	NULL
43	NULL
,	NULL
46	NULL
)	NULL
.	NULL

Several	NULL
GEFs	NULL
for	NULL
the	NULL
Rho	NULL
family	NULL
,	NULL
such	NULL
as	NULL
Ost	NULL
(	NULL
23	NULL
)	NULL
,	NULL
Tiam	NULL
(	NULL
29	NULL
)	NULL
,	NULL
and	NULL
the	NULL
faciogenital	NULL
dysplasia	NULL
gene	NULL
product	NULL
(	NULL
FGD1	NULL
[	NULL
39	NULL
]	NULL
)	NULL
,	NULL
have	NULL
been	NULL
isolated	NULL
and	NULL
shown	NULL
to	NULL
promote	NULL
binding	NULL
of	NULL
GTP	NULL
to	NULL
Rho	NULL
.	NULL

Ber	NULL
(	NULL
11	NULL
)	NULL
,	NULL
p190	NULL
(	NULL
8	NULL
,	NULL
45	NULL
)	NULL
,	NULL
and	NULL
Cdc42GAP	NULL
(	NULL
7	NULL
)	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
act	NULL
as	NULL
GAPs	NULL
for	NULL
the	NULL
Rho	NULL
family	NULL
,	NULL
promoting	NULL
the	NULL
conversion	NULL
of	NULL
GTP	NULL
to	NULL
GDP	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
Rho	NULL
family	NULL
members	NULL
in	NULL
cellular	NULL
activation	NULL
and	NULL
growth	NULL
has	NULL
been	NULL
underscored	NULL
by	NULL
several	NULL
recent	NULL
stud-ies	NULL
.	NULL

In	NULL
NIH	NULL
3T3	NULL
cells	NULL
,	NULL
coexpression	NULL
of	NULL
oncogenic	NULL
Ras	NULL
(	NULL
61L	NULL
)	NULL
with	NULL
activated	NULL
Rho	NULL
(	NULL
63L	NULL
)	NULL
enhances	NULL
morphological	NULL
transformation	NULL
and	NULL
cell	NULL
motility	NULL
.	NULL

Overexpression	NULL
of	NULL
dominant-negative	NULL
(	NULL
DN	NULL
)	NULL
mutants	NULL
of	NULL
Rac	NULL
or	NULL
Rho	NULL
reduces	NULL
oncogenic	NULL
Ras	NULL
transforming	NULL
activity	NULL
,	NULL
indicating	NULL
that	NULL
activation	NULL
of	NULL
Rho	NULL
is	NULL
required	NULL
for	NULL
Ras	NULL
transformation	NULL
(	NULL
26	NULL
,	NULL
40	NULL
)	NULL
.	NULL

Roles	NULL
for	NULL
Rho	NULL
in	NULL
gene	NULL
regulation	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
have	NULL
also	NULL
been	NULL
demonstrated	NULL
.	NULL

Microinjection	NULL
of	NULL
activated	NULL
forms	NULL
of	NULL
Rho	NULL
,	NULL
Rac	NULL
,	NULL
and	NULL
Cdc42Hs	NULL
stimulates	NULL
cell	NULL
cycle	NULL
progression	NULL
and	NULL
subsequent	NULL
DNA	NULL
synthe-sis	NULL
.	NULL

Serum-induced	NULL
DNA	NULL
synthesis	NULL
and	NULL
progression	NULL
through	NULL
the	NULL
G	NULL
,	NULL
phase	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
microinjection	NULL
of	NULL
C3	NULL
exoenzyme	NULL
(	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
Rho	NULL
)	NULL
or	NULL
by	NULL
expression	NULL
of	NULL
DN	NULL
Rac	NULL
or	NULL
Cdc42Hs	NULL
(	NULL
38	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
thymuses	NULL
lacking	NULL
functional	NULL
Rho	NULL
isolated	NULL
from	NULL
transgenic	NULL
mice	NULL
that	NULL
overexpress	NULL
C3	NULL
exoenzyme	NULL
are	NULL
small	NULL
and	NULL
show	NULL
markedly	NULL
decreased	NULL
cellularity	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Other	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Division	NULL
of	NULL
Pediatric	NULL
Oncology	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
44	NULL
Binney	NULL
St.	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
617	NULL
)	NULL
632-3564	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
617	NULL
)	NULL
632-4367	NULL
.	NULL

E-mail	NULL
:	NULL
steven_burakof	NULL
@	NULL
dfci.harvard.edu	NULL
.	NULL

4986	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
Rho	NULL
is	NULL
required	NULL
for	NULL
survival	NULL
of	NULL
early	NULL
pre-T	NULL
cells	NULL
and	NULL
regulates	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
late	NULL
pre-T	NULL
cells	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
by	NULL
which	NULL
Rho	NULL
regulates	NULL
such	NULL
diverse	NULL
cellular	NULL
processes	NULL
is	NULL
not	NULL
well	NULL
understood	NULL
.	NULL

One	NULL
possibility	NULL
is	NULL
that	NULL
Rho	NULL
mediates	NULL
distinct	NULL
cellular	NULL
functions	NULL
through	NULL
control	NULL
of	NULL
transcriptional	NULL
activation	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
hypothesis	NULL
,	NULL
reports	NULL
have	NULL
demonstrated	NULL
that	NULL
activated	NULL
Rho	NULL
regulates	NULL
c-fos	NULL
promoter	NULL
activity	NULL
by	NULL
serum	NULL
response	NULL
factor	NULL
(	NULL
SRF	NULL
)	NULL
and	NULL
that	NULL
this	NULL
activity	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
C3	NULL
exoenzyme	NULL
(	NULL
1	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Fos	NULL
interacts	NULL
with	NULL
c-Jun	NULL
and	NULL
subsequently	NULL
controls	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
a	NULL
number	NULL
of	NULL
other	NULL
genes	NULL
involved	NULL
in	NULL
many	NULL
cell	NULL
programs	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
consists	NULL
of	NULL
a	NULL
family	NULL
of	NULL
structurally	NULL
related	NULL
serine/threonine	NULL
kinases	NULL
that	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
cell	NULL
proliferation	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
transformation	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

PKCs	NULL
are	NULL
divided	NULL
into	NULL
three	NULL
major	NULL
subgroups	NULL
(	NULL
conventional	NULL
,	NULL
novel	NULL
,	NULL
and	NULL
atypical	NULL
)	NULL
defined	NULL
by	NULL
their	NULL
structures	NULL
and	NULL
their	NULL
abilities	NULL
to	NULL
be	NULL
regulated	NULL
by	NULL
calcium	NULL
and/or	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
.	NULL

Conventional	NULL
PKCs	NULL
contain	NULL
a	NULL
C-terminal	NULL
catalytic	NULL
domain	NULL
and	NULL
an	NULL
N-terminal	NULL
regulatory	NULL
domain	NULL
that	NULL
is	NULL
composed	NULL
of	NULL
a	NULL
pseudosubstrate	NULL
site	NULL
,	NULL
a	NULL
C1	NULL
domain	NULL
that	NULL
binds	NULL
diacylglyc-erol	NULL
(	NULL
DAG	NULL
)	NULL
or	NULL
its	NULL
analog	NULL
PMA	NULL
,	NULL
and	NULL
a	NULL
C2	NULL
domain	NULL
that	NULL
binds	NULL
calcium	NULL
and	NULL
phospholipid	NULL
.	NULL

The	NULL
cellular	NULL
roles	NULL
of	NULL
the	NULL
different	NULL
PKC	NULL
isozymes	NULL
remain	NULL
unclear	NULL
,	NULL
but	NULL
accumulated	NULL
evidence	NULL
has	NULL
shown	NULL
that	NULL
individual	NULL
PKC	NULL
isoforms	NULL
may	NULL
play	NULL
distinct	NULL
roles	NULL
in	NULL
response	NULL
to	NULL
various	NULL
activating	NULL
stimuli	NULL
.	NULL

For	NULL
example	NULL
,	NULL
overexpression	NULL
of	NULL
PKC	NULL
enhances	NULL
the	NULL
growth	NULL
rate	NULL
of	NULL
NIH	NULL
3T3	NULL
cells	NULL
,	NULL
while	NULL
overexpression	NULL
of	NULL
PKC8	NULL
decreases	NULL
cell	NULL
growth	NULL
rate	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
important	NULL
role	NULL
of	NULL
PKCs	NULL
in	NULL
signal	NULL
transduction	NULL
is	NULL
evident	NULL
from	NULL
their	NULL
substrate	NULL
specificity	NULL
,	NULL
subcellular	NULL
localization	NULL
,	NULL
sensitivity	NULL
to	NULL
downregulation	NULL
via	NULL
agonist	NULL
induction	NULL
and	NULL
regulation	NULL
of	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Interaction	NULL
of	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
with	NULL
antigen	NULL
in	NULL
the	NULL
context	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex	NULL
proteins	NULL
initiates	NULL
a	NULL
signal	NULL
transduction	NULL
cascade	NULL
that	NULL
leads	NULL
to	NULL
transcriptional	NULL
activation	NULL
,	NULL
lymphokine	NULL
production	NULL
,	NULL
cell	NULL
proliferation	NULL
,	NULL
and	NULL
induction	NULL
of	NULL
the	NULL
cell	NULL
's	NULL
effector	NULL
function	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
TCR	NULL
,	NULL
other	NULL
costimulatory	NULL
surface	NULL
molecules	NULL
,	NULL
such	NULL
as	NULL
CD28	NULL
,	NULL
Vou	NULL
.	NULL

18	NULL
,	NULL
1998	NULL
contribute	NULL
to	NULL
T-cell	NULL
signaling	NULL
(	NULL
14	NULL
)	NULL
.	NULL

T-cell	NULL
activation	NULL
via	NULL
anti-TCR	NULL
and	NULL
anti-CD28	NULL
antibody-mediated	NULL
costimulation	NULL
markedly	NULL
enhances	NULL
the	NULL
production	NULL
of	NULL
several	NULL
cytokines	NULL
,	NULL
including	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
IL-3	NULL
,	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
,	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
(	NULL
51	NULL
)	NULL
,	NULL
and	NULL
also	NULL
results	NULL
in	NULL
cellular	NULL
proliferation	NULL
and	NULL
functional	NULL
activation	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
transcription	NULL
factors	NULL
to	NULL
specific	NULL
sites	NULL
within	NULL
the	NULL
promoters	NULL
of	NULL
these	NULL
cytokine	NULL
genes	NULL
is	NULL
responsible	NULL
for	NULL
their	NULL
up-regulation	NULL
.	NULL

A	NULL
300-bp	NULL
IL-2	NULL
promoter	NULL
(	NULL
IL-2P	NULL
)	NULL
region	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
is	NULL
sufficient	NULL
to	NULL
transcriptionally	NULL
regulate	NULL
IL-2	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
TCR	NULL
stimulation	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Several	NULL
transcription	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
NFAT	NULL
,	NULL
Oct-1	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
NF-kB	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
to	NULL
identified	NULL
enhancer	NULL
elements	NULL
in	NULL
the	NULL
IL-2P	NULL
.	NULL

In	NULL
lymphocytes	NULL
,	NULL
Fos	NULL
and	NULL
Jun	NULL
form	NULL
a	NULL
competent	NULL
transcription	NULL
factor	NULL
complex	NULL
that	NULL
activates	NULL
the	NULL
AP-1	NULL
enhancer	NULL
elements	NULL
within	NULL
the	NULL
promoters	NULL
for	NULL
several	NULL
genes	NULL
of	NULL
diverse	NULL
function	NULL
,	NULL
such	NULL
as	NULL
granzyme	NULL
B	NULL
,	NULL
CD11c	NULL
,	NULL
CD40L	NULL
,	NULL
and	NULL
CD69	NULL
genes	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
cytokine	NULL
promoters	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
apparent	NULL
that	NULL
regulation	NULL
of	NULL
the	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
is	NULL
integral	NULL
to	NULL
the	NULL
control	NULL
of	NULL
many	NULL
aspects	NULL
of	NULL
immune	NULL
function	NULL
,	NULL
including	NULL
cytokine	NULL
production	NULL
,	NULL
cytolytic	NULL
effector	NULL
function	NULL
,	NULL
adhesion	NULL
,	NULL
and	NULL
cell	NULL
survival	NULL
and	NULL
proliferation	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
overexpression	NULL
of	NULL
activated	NULL
Rho	NULL
synergizes	NULL
with	NULL
PMA	NULL
to	NULL
augment	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

Overexpression	NULL
of	NULL
CAAX-deleted	NULL
activated	NULL
Rho	NULL
abolishes	NULL
the	NULL
enhancement	NULL
.	NULL

This	NULL
effect	NULL
is	NULL
not	NULL
mediated	NULL
through	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
(	NULL
MAPK	NULL
)	NULL
pathway	NULL
,	NULL
as	NULL
it	NULL
is	NULL
not	NULL
affected	NULL
by	NULL
overexpression	NULL
of	NULL
DN	NULL
MEK	NULL
or	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
MEK	NULL
inhibitor	NULL
.	NULL

The	NULL
plasma	NULL
membrane-asso-ciated	NULL
Rho	NULL
binds	NULL
to	NULL
PKCa	NULL
but	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
PKCB	NULL
,	NULL
-y	NULL
,	NULL
or	NULL
-g.	NULL
In	NULL
addition	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
N-terminal	NULL
regulatory	NULL
domain	NULL
of	NULL
PKCa	NULL
blocks	NULL
activated	NULL
Rho-plus-PMA-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
small	NULL
GTP-binding	NULL
protein	NULL
,	NULL
Rho	NULL
,	NULL
potentiates	NULL
AP-1	NULL
enhancer	NULL
element	NULL
activity	NULL
and	NULL
may	NULL
augment	NULL
AP-1l-containing	NULL
gene	NULL
transcription	NULL
following	NULL
T-cell	NULL
activation	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Reagents	NULL
.	NULL

Anti-PKCo	NULL
,	NULL
-y	NULL
,	NULL
and	NULL
-g	NULL
and	NULL
anti-glutathione	NULL
S-transferase	NULL
(	NULL
GST	NULL
)	NULL
antibodies	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
to	NULL
PKCa	NULL
and	NULL
-B	NULL
were	NULL
purchased	NULL
from	NULL
Transduction	NULL
Laboratories	NULL
(	NULL
Lexington	NULL
,	NULL
Ky.	NULL
)	NULL
.	NULL

Anti-CD28	NULL
(	NULL
clone	NULL
9.3	NULL
)	NULL
was	NULL
a	NULL
gift	NULL
of	NULL
C.	NULL
Thompson	NULL
(	NULL
University	NULL
of	NULL
Chicago	NULL
,	NULL
Chicago	NULL
,	NULL
IIL	NULL
)	NULL
.	NULL

Anti-c-Myc	NULL
antibody	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

.	NULL

Cyclosporin	NULL
A	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Sandoz	NULL
Laboratory	NULL
(	NULL
East	NULL
Hanover	NULL
,	NULL
N.J.	NULL
)	NULL
.	NULL

The	NULL
PKC	NULL
inhibitor	NULL
RO318820	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Hoffman-La	NULL
Roche	NULL
(	NULL
Nutley	NULL
,	NULL
N.J.	NULL
)	NULL
,	NULL
and	NULL
FK506	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Fujisawa	NULL
(	NULL
Melrose	NULL
Park	NULL
,	NULL
III	NULL
.	NULL
)	NULL

.	NULL

Rapamycin	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
J.	NULL
Johnson	NULL
(	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

.	NULL

Ionomycin	NULL
and	NULL
PMA	NULL
were	NULL
purchased	NULL
from	NULL
Calbiochem	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Glutathione-Sepharose	NULL
beads	NULL
were	NULL
purchased	NULL
from	NULL
Pharmacia	NULL
Biotechnology	NULL
(	NULL
Piscataway	NULL
,	NULL
N.J.	NULL
)	NULL
.	NULL

Wortmannin	NULL
was	NULL
purchased	NULL
from	NULL
Sigma	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

.	NULL

The	NULL
MEK	NULL
inhibitor	NULL
PD98059	NULL
was	NULL
purchased	NULL
from	NULL
New	NULL
England	NULL
Biolabs	NULL
(	NULL
Beverly	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

.	NULL

A	NULL
luciferase	NULL
assay	NULL
kit	NULL
was	NULL
purchased	NULL
from	NULL
Analytical	NULL
Luminescence	NULL
Laboratory	NULL
(	NULL
Ann	NULL
Arbor	NULL
,	NULL
Mich.	NULL
)	NULL
.	NULL

Cells	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
clone	NULL
J77	NULL
)	NULL
were	NULL
cultured	NULL
at	NULL
37°C	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
100	NULL
pg	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
100	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
1-glutamine	NULL
.	NULL

Molecular	NULL
constructs	NULL
.	NULL

cDNAs	NULL
encoding	NULL
human	NULL
RhoA	NULL
,	NULL
Cdc42	NULL
,	NULL
and	NULL
Rac	NULL
were	NULL
generously	NULL
provided	NULL
by	NULL
Alan	NULL
Hall	NULL
(	NULL
MRC	NULL
Laboratory	NULL
for	NULL
Molecular	NULL
Cell	NULL
Biology	NULL
,	NULL
University	NULL
College	NULL
London	NULL
,	NULL
London	NULL
,	NULL
England	NULL
)	NULL
.	NULL

V14Rho	NULL
,	NULL
N19Rho	NULL
,	NULL
and	NULL
V14Rho-ACAAX	NULL
were	NULL
generated	NULL
via	NULL
oligonucleotide-directed	NULL
mutagenesis	NULL
from	NULL
human	NULL
RhoA	NULL
,	NULL
and	NULL
V12Ras	NULL
was	NULL
generated	NULL
from	NULL
H-Ras	NULL
(	NULL
provided	NULL
by	NULL
J.	NULL
Settleman	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

by	NULL
the	NULL
Teg	NULL
PCR	NULL
method	NULL
.	NULL

The	NULL
PCR	NULL
products	NULL
were	NULL
subcloned	NULL
into	NULL
the	NULL
pEBG	NULL
vector	NULL
(	NULL
provided	NULL
by	NULL
B.	NULL
Mayer	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
)	NULL
,	NULL
which	NULL
generated	NULL
a	NULL
GST	NULL
fusion	NULL
protein	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
human	NULL
elongation	NULL
factor	NULL
1	NULL
promoter	NULL
.	NULL

A	NULL
human	NULL
IL-2P	NULL
luciferase	NULL
construct	NULL
,	NULL
containing	NULL
400	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
initiation	NULL
of	NULL
transcription	NULL
site	NULL
,	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
T.	NULL
Williams	NULL
(	NULL
University	NULL
of	NULL
New	NULL
Mexico	NULL
,	NULL
Albuquerque	NULL
)	NULL
.	NULL

A	NULL
construct	NULL
encoding	NULL
a	NULL
DN	NULL
MEK	NULL
,	NULL
in	NULL
which	NULL
Ser	NULL
221	NULL
was	NULL
mutated	NULL
to	NULL
Ala	NULL
,	NULL
was	NULL
provided	NULL
by	NULL
Sally	NULL
Cowley	NULL
(	NULL
Institute	NULL
of	NULL
Cancer	NULL
Research	NULL
,	NULL
London	NULL
,	NULL
England	NULL
)	NULL
and	NULL
subcloned	NULL
into	NULL
the	NULL
pEBG	NULL
vector	NULL
(	NULL
GST-MEKS221A	NULL
)	NULL
.	NULL

Wild-type	NULL
(	NULL
wt	NULL
)	NULL
and	NULL
kinase-defective	NULL
forms	NULL
of	NULL
bovine	NULL
PKCa	NULL
(	NULL
provided	NULL
by	NULL
A.	NULL
Altman	NULL
,	NULL
La	NULL
Jolla	NULL
Institute	NULL
for	NULL
Allergy	NULL
and	NULL
Immunology	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
Calif.	NULL
)	NULL
were	NULL
tagged	NULL
at	NULL
the	NULL
N	NULL
terminus	NULL
with	NULL
amino	NULL
acids	NULL
MEQKLISE	NULL
Rho	NULL
REGULATES	NULL
AP-1	NULL
TRANSCRIPTIONAL	NULL
ACTIVATION	NULL
-	NULL
4987	NULL
EDL	NULL
of	NULL
c-Myc	NULL
and	NULL
expressed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
human	NULL
elongation	NULL
factor	NULL
1	NULL
promoter	NULL
(	NULL
pEBB	NULL
)	NULL
.	NULL

The	NULL
N-terminal	NULL
regulatory	NULL
domain	NULL
(	NULL
residues	NULL
1	NULL
to	NULL
300	NULL
)	NULL
of	NULL
bovine	NULL
PKCa	NULL
(	NULL
N-PKCa	NULL
)	NULL
was	NULL
subcloned	NULL
into	NULL
pEBB	NULL
.	NULL

The	NULL
minimal	NULL
IL-2	NULL
TATA	NULL
box	NULL
luciferase	NULL
construct	NULL
[	NULL
pGL2	NULL
(	NULL
mini-IL-2	NULL
)	NULL
]	NULL
was	NULL
generated	NULL
by	NULL
annealing	NULL
synthesized	NULL
complementary	NULL
oligonucleotide	NULL
strands	NULL
that	NULL
were	NULL
subsequently	NULL
cloned	NULL
into	NULL
the	NULL
Bgill	NULL
and	NULL
HindIII	NULL
sites	NULL
of	NULL
the	NULL
pGL2	NULL
vector	NULL
.	NULL

All	NULL
individual	NULL
IL-2	NULL
enhancer	NULL
element	NULL
reporter	NULL
constructs	NULL
were	NULL
generated	NULL
by	NULL
the	NULL
method	NULL
described	NULL
above	NULL
but	NULL
were	NULL
cloned	NULL
into	NULL
the	NULL
and	NULL
Bg/II	NULL
sites	NULL
of	NULL
pGL2	NULL
(	NULL
mini-IL-2	NULL
)	NULL
.	NULL

Transient	NULL
transfection	NULL
assays	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
(	NULL
10	NULL
'	NULL
)	NULL
were	NULL
suspended	NULL
in	NULL
500	NULL
pl	NULL
of	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
elec-troporated	NULL
at	NULL
800	NULL
F	NULL
and	NULL
250	NULL
V	NULL
in	NULL
a	NULL
BRL	NULL
electroporator	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
2	NULL
pg	NULL
of	NULL
pRSV-Bgal	NULL
and	NULL
IL-2P	NULL
luciferase	NULL
constructs	NULL
in	NULL
addition	NULL
to	NULL
20	NULL
g	NULL
of	NULL
the	NULL
experimental	NULL
construct	NULL
.	NULL

The	NULL
transfected	NULL
cells	NULL
were	NULL
grown	NULL
for	NULL
15	NULL
h	NULL
,	NULL
and	NULL
aliquots	NULL
of	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
inhibitors	NULL
or	NULL
stimulators	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
figure	NULL
legends	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
Tris-buffered	NULL
saline	NULL
and	NULL
lysed	NULL
.	NULL

Luciferase	NULL
activities	NULL
were	NULL
determined	NULL
with	NULL
a	NULL
luminom-eter	NULL
and	NULL
normalized	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
B-galactosidase	NULL
expression	NULL
and/or	NULL
the	NULL
level	NULL
of	NULL
transfected	NULL
GST	NULL
fusion	NULL
proteins	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
IL-2P-driven	NULL
luciferase	NULL
activation	NULL
,	NULL
which	NULL
was	NULL
determined	NULL
by	NULL
dividing	NULL
luciferase	NULL
activity	NULL
of	NULL
experimental	NULL
conditions	NULL
by	NULL
the	NULL
activity	NULL
obtained	NULL
in	NULL
unstimulated	NULL
cells	NULL
transfected	NULL
with	NULL
vector	NULL
.	NULL

Individual	NULL
experiments	NULL
were	NULL
performed	NULL
at	NULL
least	NULL
twice	NULL
,	NULL
and	NULL
cach	NULL
experiment	NULL
was	NULL
done	NULL
in	NULL
duplicate	NULL
.	NULL

Subcellular	NULL
fractionation	NULL
.	NULL

Cytosolic	NULL
and	NULL
membrane	NULL
fractions	NULL
were	NULL
prepared	NULL
from	NULL
Rho-	NULL
and	NULL
Rho	NULL
mutant-expressing	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
Tris-buffered	NULL
saline	NULL
and	NULL
resuspended	NULL
in	NULL
hypotonic	NULL
solution	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.0	NULL
]	NULL
,	NULL
10	NULL
mM	NULL
KCI	NULL
,	NULL
2	NULL
mM	NULL
MgC	NULL
)	NULL
;	NULL
,	NULL
protease	NULL
and	NULL
phosphatase	NULL
inhibitors	NULL
)	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
homogenized	NULL
by	NULL
20	NULL
strokes	NULL
in	NULL
a	NULL
tight-fitting	NULL
Dounce	NULL
homog-enizer	NULL
(	NULL
type	NULL
A	NULL
)	NULL
,	NULL
and	NULL
nuclei	NULL
were	NULL
sedimented	NULL
at	NULL
1,500	NULL
x	NULL
g	NULL
for	NULL
5	NULL
min	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
resedimented	NULL
at	NULL
100,000	NULL
x	NULL
g	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
designated	NULL
the	NULL
cytosol	NULL
,	NULL
and	NULL
the	NULL
pellet	NULL
was	NULL
designated	NULL
the	NULL
membrane	NULL
fraction	NULL
.	NULL

The	NULL
washed	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
lysis	NULL
buffer	NULL
containing	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
50	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
8	NULL
)	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
50	NULL
ug	NULL
of	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
per	NULL
ml	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
leupeptin	NULL
per	NULL
ml	NULL
,	NULL
5	NULL
pg	NULL
of	NULL
aprotinin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
sodium	NULL
vanadate	NULL
and	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Insoluble	NULL
material	NULL
was	NULL
removed	NULL
by	NULL
centrifugation	NULL
.	NULL

Immunoblotting	NULL
(	NULL
Western	NULL
)	NULL
analysis	NULL
.	NULL

Cells	NULL
(	NULL
10	NULL
``	NULL
)	NULL
were	NULL
lysed	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
in	NULL
500	NULL
pul	NULL
of	NULL
lysis	NULL
buffer	NULL
.	NULL

Lysates	NULL
were	NULL
clarified	NULL
by	NULL
centrifugation	NULL
at	NULL
4°C	NULL
for	NULL
15	NULL
min	NULL
at	NULL
13,000	NULL
X	NULL
g.	NULL
Lysates	NULL
were	NULL
precleared	NULL
by	NULL
protein	NULL
A-Sepharose	NULL
or	NULL
glutathione-Sepharose	NULL
beads	NULL
and	NULL
subjected	NULL
to	NULL
immunoprecipitation	NULL
with	NULL
the	NULL
indicated	NULL
antibodies	NULL
.	NULL

The	NULL
immunocomplexes	NULL
were	NULL
further	NULL
characterized	NULL
by	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
,	NULL
transferred	NULL
onto	NULL
Immobilon	NULL
mem-branes	NULL
,	NULL
and	NULL
immunoblotted	NULL
with	NULL
antibodies	NULL
as	NULL
indicated	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
exogenous	NULL
wt	NULL
and	NULL
mutated	NULL
forms	NULL
of	NULL
Rho	NULL
and	NULL
Ras	NULL
proteins	NULL
was	NULL
determined	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
using	NULL
anti-GST	NULL
antibodies	NULL
.	NULL

RESULTS	NULL
Small	NULL
GTP-binding	NULL
proteins	NULL
potentiate	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
following	NULL
PMA	NULL
stimulation	NULL
.	NULL

Most	NULL
cytokine	NULL
genes	NULL
contain	NULL
several	NULL
transcriptional	NULL
elements	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
that	NULL
exert	NULL
tight	NULL
control	NULL
of	NULL
gene	NULL
transcription	NULL
following	NULL
stimulation	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
IL-2P	NULL
is	NULL
the	NULL
most	NULL
extensively	NULL
studied	NULL
model	NULL
of	NULL
cytokine	NULL
transcriptional	NULL
regulation	NULL
.	NULL

The	NULL
minimal	NULL
IL-2P	NULL
contains	NULL
several	NULL
regulatory	NULL
elements	NULL
,	NULL
including	NULL
a	NULL
TATA	NULL
box	NULL
and	NULL
AP-1	NULL
,	NULL
Oct-1	NULL
,	NULL
NFAT	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
and	NULL
CD28	NULL
response	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
binding	NULL
sites	NULL
(	NULL
5	NULL
,	NULL
34	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
is	NULL
controlled	NULL
by	NULL
distinct	NULL
regulatory	NULL
proteins	NULL
.	NULL

For	NULL
example	NULL
,	NULL
NFAT	NULL
binding	NULL
is	NULL
regulated	NULL
by	NULL
calcineurin	NULL
,	NULL
NF-kB	NULL
binding	NULL
is	NULL
regulated	NULL
by	NULL
IB	NULL
,	NULL
and	NULL
AP-1	NULL
protein	NULL
binding	NULL
is	NULL
regulated	NULL
by	NULL
PKC	NULL
(	NULL
13	NULL
,	NULL
48	NULL
)	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
Rho	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
affect	NULL
T-cell	NULL
functions	NULL
(	NULL
17	NULL
)	NULL
,	NULL
and	NULL
Rho	NULL
in	NULL
nonlymphoid	NULL
cells	NULL
regulates	NULL
transcription	NULL
of	NULL
c-fos	NULL
.	NULL

To	NULL
address	NULL
the	NULL
effect	NULL
of	NULL
Rho	NULL
on	NULL
transcriptional	NULL
activation	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
luciferase	NULL
reporter	NULL
constructs	NULL
that	NULL
contain	NULL
the	NULL
IL-2P	NULL
TATA	NULL
box	NULL
region	NULL
and/or	NULL
a	NULL
combination	NULL
of	NULL
three	NULL
or	NULL
five	NULL
repeats	NULL
of	NULL
individual	NULL
IL-2P	NULL
elements	NULL
(	NULL
AP-1	NULL
,	NULL
Oct-1	NULL
,	NULL
NFAT	NULL
,	NULL
NF-kB	NULL
,	NULL
and	NULL
CD28RE	NULL
)	NULL
were	NULL
generated	NULL
as	NULL
listed	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

These	NULL
reporter	NULL
constructs	NULL
,	NULL
in	NULL
combination	NULL
with	NULL
vector	NULL
(	NULL
pEBG	NULL
)	NULL
or	NULL
pEBG-V14rho	NULL
,	NULL
were	NULL
transiently	NULL
transfected	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
stimulated	NULL
with	NULL
10	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
.	NULL

In	NULL
cells	NULL
transfected	NULL
with	NULL
vector	NULL
alone	NULL
,	NULL
PMA	NULL
induced	NULL
minimal	NULL
transcriptional	NULL
activity	NULL
of	NULL
each	NULL
IL-2	NULL
enhancer	NULL
element	NULL
.	NULL

In	NULL
cells	NULL
that	NULL
overexpress	NULL
activated	NULL
Rho	NULL
,	NULL
the	NULL
basal	NULL
transcriptional	NULL
activity	NULL
of	NULL
each	NULL
enhancer	NULL
element	NULL
was	NULL
increased	NULL
three-	NULL
to	NULL
fivefold	NULL
compared	NULL
to	NULL
vector-transfected	NULL
4988	NULL
CHANG	NULL
ET	NULL
AL	NULL
.	NULL

TABLE	NULL
1	NULL
.	NULL

IL-2	NULL
enhancer	NULL
element	NULL
reporter	NULL
constructs	NULL
Location	NULL
relative	NULL
Construct	NULL
Sequence	NULL
to	NULL
initiation	NULL
site	NULL
pGL2	NULL
(	NULL
Oct-1	NULL
}	NULL
)	NULL
(	NULL
atgtaaaac	NULL
)	NULL
,	NULL
-90	NULL
to	NULL
-81	NULL
pGL2	NULL
(	NULL
Oct-1/AP-1	NULL
)	NULL
(	NULL
tgtgtaattatgtaaac	NULL
)	NULL
,	NULL
-99	NULL
to	NULL
-81	NULL
pGL2	NULL
(	NULL
-140	NULL
AP-1	NULL
)	NULL
(	NULL
ccaaagagtca	NULL
)	NULL
,	NULL
-147	NULL
to	NULL
-136	NULL
pGL2	NULL
(	NULL
CD28RE	NULL
)	NULL
(	NULL
agaaattcca	NULL
)	NULL
s	NULL
-162	NULL
to	NULL
-154	NULL
pGL2	NULL
(	NULL
CD28RE/AP-1	NULL
)	NULL
-	NULL
(	NULL
agaaattccaaagagtcatcag	NULL
)	NULL
,	NULL
-	NULL
-162	NULL
to	NULL
-142	NULL
pGL2	NULL
(	NULL
NFAT	NULL
)	NULL
(	NULL
gaggaaaaac	NULL
)	NULL
;	NULL
,	NULL
-288	NULL
to	NULL
-278	NULL
pGL2	NULL
(	NULL
NFAT/AP-1	NULL
)	NULL
(	NULL
gaggaaaaactgtttcata	NULL
)	NULL
,	NULL
-288	NULL
to	NULL
-268	NULL
pGL2	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
(	NULL
eggatttcacc	NULL
)	NULL
,	NULL
-207	NULL
to	NULL
-197	NULL
pGL2	NULL
(	NULL
mini-IL-2	NULL
)	NULL
gcagttaacagtataaattgcatct	NULL
-	NULL
-40	NULL
to	NULL
+6	NULL
cttgttcaagagttcectatcactc	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

The	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
AP-1	NULL
(	NULL
-140	NULL
region	NULL
)	NULL
element	NULL
(	NULL
-140	NULL
AP-1	NULL
)	NULL
was	NULL
potentiated	NULL
20-	NULL
to	NULL
30-fold	NULL
following	NULL
PMA	NULL
stimulation	NULL
in	NULL
V14Rho-transfected	NULL
cells	NULL
.	NULL

The	NULL
transcriptional	NULL
activity	NULL
of	NULL
each	NULL
of	NULL
the	NULL
remaining	NULL
enhancer	NULL
elements	NULL
increased	NULL
approximately	NULL
5-	NULL
to	NULL
10-fold	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PMA	NULL
in	NULL
V14Rho-transfected	NULL
cells	NULL
compared	NULL
to	NULL
vector-transfected	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
V14Rho	NULL
has	NULL
a	NULL
potent	NULL
effect	NULL
on	NULL
the	NULL
-140	NULL
AP-1	NULL
enhancer	NULL
element	NULL
within	NULL
the	NULL
IL-2P	NULL
.	NULL

Rho	NULL
family	NULL
members	NULL
have	NULL
distinct	NULL
functions	NULL
in	NULL
cytoskeletal	NULL
rearrangement	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Rho	NULL
regulates	NULL
stress	NULL
fiber	NULL
formation	NULL
,	NULL
Rac	NULL
regulates	NULL
lamellipodia	NULL
,	NULL
and	NULL
Cdc42	NULL
triggers	NULL
the	NULL
formation	NULL
of	NULL
filopodia	NULL
.	NULL

To	NULL
address	NULL
if	NULL
Cdc42	NULL
and	NULL
Rac	NULL
are	NULL
also	NULL
involved	NULL
in	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
,	NULL
pEBG-V12rac	NULL
and	NULL
pEBG-V12edc42	NULL
were	NULL
cotransfected	NULL
with	NULL
pGL2	NULL
(	NULL
-140	NULL
AP-1	NULL
)	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
-140	NULL
AP-1	NULL
was	NULL
potentiated	NULL
20-fold	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PMA	NULL
in	NULL
pEBG-V12ecdc42-transfected	NULL
cells	NULL
and	NULL
about	NULL
10-fold	NULL
in	NULL
pEBG-V12rac-transfected	NULL
cells	NULL
.	NULL

Rho	NULL
associates	NULL
with	NULL
PKCa	NULL
.	NULL

Pkclp	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
associate	NULL
with	NULL
Rholp	NULL
and	NULL
to	NULL
act	NULL
as	NULL
its	NULL
downstream	NULL
target	NULL
in	NULL
Sec-charomyces	NULL
cerevisiae	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Given	NULL
the	NULL
marked	NULL
effect	NULL
of	NULL
V14Rho	NULL
on	NULL
the	NULL
AP-1	NULL
enhancer	NULL
element	NULL
,	NULL
we	NULL
set	NULL
out	NULL
to	NULL
investigate	NULL
the	NULL
possibility	NULL
that	NULL
Rho	NULL
associates	NULL
with	NULL
PKC	NULL
family	NULL
members	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
precipitated	NULL
proteins	NULL
that	NULL
associated	NULL
with	NULL
GST-V14Rho	NULL
,	NULL
using	NULL
antibodies	NULL
specific	NULL
for	NULL
PKCa	NULL
,	NULL
-B	NULL
,	NULL
-y	NULL
,	NULL
and	NULL
-£	NULL
,	NULL
revealed	NULL
that	NULL
only	NULL
PKCa	NULL
,	NULL
not	NULL
PKCB	NULL
,	NULL
-y	NULL
,	NULL
or	NULL
-g	NULL
,	NULL
associated	NULL
with	NULL
activated	NULL
GST	NULL
-Rho	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

The	NULL
anti-PKCa	NULL
antibodies	NULL
did	NULL
not	NULL
cross-react	NULL
with	NULL
PKN	NULL
,	NULL
a	NULL
PKC-like	NULL
serine/	NULL
threonine	NULL
kinase	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
GST	NULL
fusion	NULL
proteins	NULL
were	NULL
expressed	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

To	NULL
further	NULL
characterize	NULL
this	NULL
association	NULL
,	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
vector	NULL
or	NULL
V14Rho	NULL
and	NULL
subjected	NULL
to	NULL
subcellular	NULL
fractionation	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
PKCa	NULL
constitutively	NULL
associated	NULL
with	NULL
V14Rho	NULL
in	NULL
the	NULL
membrane	NULL
fraction	NULL
only	NULL
;	NULL
however	NULL
,	NULL
V14Rho	NULL
was	NULL
equally	NULL
distributed	NULL
in	NULL
the	NULL
membrane	NULL
and	NULL
cytosolic	NULL
fractions	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
GST	NULL
was	NULL
found	NULL
only	NULL
in	NULL
the	NULL
cytosol	NULL
(	NULL
Fig	NULL
.	NULL

2D	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
structural	NULL
requirement	NULL
of	NULL
Rho	NULL
for	NULL
its	NULL
association	NULL
with	NULL
PKCa	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
transiently	NULL
overexpressed	NULL
activated	NULL
V14Rho	NULL
,	NULL
wt	NULL
Rho	NULL
,	NULL
DN	NULL
N19Rho	NULL
,	NULL
and	NULL
V14Rho-ACAAX	NULL
(	NULL
a	NULL
Rho	NULL
construct	NULL
that	NULL
lacks	NULL
four	NULL
amino	NULL
acids	NULL
necessary	NULL
for	NULL
membrane	NULL
localization	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2E	NULL
,	NULL
PKCa	NULL
associated	NULL
strongly	NULL
with	NULL
V14Rho	NULL
,	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
with	NULL
wt	NULL
Rho	NULL
,	NULL
and	NULL
N19Rho	NULL
,	NULL
and	NULL
only	NULL
weakly	NULL
with	NULL
V14Rho-ACAAX	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
GST	NULL
fusion	NULL
proteins	NULL
were	NULL
expressed	NULL
(	NULL
Fig	NULL
.	NULL

2F	NULL
)	NULL
.	NULL

I	NULL
)	NULL
£ﬂ'ector	NULL
domains	NULL
and	NULL
localization	NULL
of	NULL
V14Rho	NULL
to	NULL
the	NULL
membrane	NULL
are	NULL
required	NULL
for	NULL
the	NULL
potentiation	NULL
of	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

The	NULL
crystal	NULL
structures	NULL
of	NULL
Ras-RasGAP	NULL
and	NULL
Rho-RhoGAP	NULL
complexes	NULL
have	NULL
been	NULL
solved	NULL
,	NULL
and	NULL
their	NULL
effector	NULL
domains	NULL
have	NULL
been	NULL
determined	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Amino	NULL
acids	NULL
10	NULL
to	NULL
16	NULL
of	NULL
Ras	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

307	NULL
207	NULL
Relative	NULL
luciferase	NULL
activation	NULL
107	NULL
o	NULL
NME	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
-	NULL
4	NULL
-4	NULL
-4	NULL
-4	NULL
-4	NULL
-4	NULL
-	NULL
%	NULL
-o-	NULL
>	NULL
bead	NULL
OuiptA	NULL
sasd	NULL
owpLA	NULL
saad	NULL
ouipLA	NULL
sad	NULL
ouiplA	NULL
baad	NULL
OwpIA	NULL
1	NULL
saad	NULL
owpLA	NULL
}	NULL
sagd	NULL
ouiplA	NULL
25	NULL
20	NULL
Fold	NULL
(	NULL
~140	NULL
}	NULL
AP1	NULL
luciferase	NULL
activation	NULL
o	NULL
PMA	NULL
(	NULL
1Ong/iml	NULL
)	NULL
--	NULL
+	NULL
0	NULL
-~	NULL
+	NULL
0-0	NULL
+00	NULL
-	NULL
O+	NULL
pEBG	NULL
V12CDC42	NULL
V1i2Rac	NULL
V14Rho	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

V1i4Rho-plus-PMA	NULL
enhancement	NULL
of	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
cotransfected	NULL
with	NULL
20	NULL
pg	NULL
of	NULL
pEBG	NULL
(	NULL
vector	NULL
)	NULL
or	NULL
pEBG-V1i4rho	NULL
,	NULL
2	NULL
ug	NULL
of	NULL
IL-2P	NULL
luciferase	NULL
reporter	NULL
gene	NULL
or	NULL
enhancer	NULL
element	NULL
reporter	NULL
construct	NULL
,	NULL
and	NULL
2	NULL
pg	NULL
of	NULL
pRSV-Bgal	NULL
.	NULL

After	NULL
15	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
for	NULL
7	NULL
h	NULL
,	NULL
and	NULL
AP-1-driven	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

pRSV-fBgal	NULL
activity	NULL
was	NULL
determined	NULL
to	NULL
normalize	NULL
transfection	NULL
efficiency	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
cotransfected	NULL
with	NULL
pEBG	NULL
(	NULL
vector	NULL
control	NULL
)	NULL
,	NULL
pEBG-V14rho	NULL
,	NULL
pEBG-V12ede42	NULL
,	NULL
or	NULL
pEBG-V12rac	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
pGL2	NULL
(	NULL
-140	NULL
AP-1	NULL
)	NULL
luciferase	NULL
reporter	NULL
construct	NULL
.	NULL

AP-1-driven	NULL
luciferase	NULL
activities	NULL
were	NULL
determined	NULL
.	NULL

Vou	NULL
.	NULL

18	NULL
,	NULL
1998	NULL
A	NULL
Anti-PKC	NULL
immunoblot	NULL
PKCa	NULL
__	NULL
PKCB	NULL
__	NULL
PKCy	NULL
PKCe	NULL
B	NULL
Anti-GST	NULL
immunoblot	NULL
GST-V1i4Rho	NULL
+	NULL
<	NULL
ld	NULL
«	NULL
-	NULL
»	NULL
,	NULL
a	NULL
»	NULL
GST	NULL
>	NULL
|a	NULL
»	NULL
``	NULL
ome	NULL
as	NULL
<	NULL
am	NULL
C	NULL
Anti-PKCo	NULL
.	NULL

immunoblot	NULL
E	NULL
Anti-	NULL
PKCo	NULL
:	NULL
immunoblot	NULL
c	NULL
m	NULL
c	NULL
m	NULL
ree	NULL
-	NULL
[	NULL
--	NULL
=	NULL
@	NULL
>	NULL
]	NULL
PKC	NULL
}	NULL
t	NULL
I	NULL
:	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
1	NULL
2	NULL
3	NULL
4	NULL
F	NULL
Anti-GST	NULL
immunoblot	NULL
D	NULL
Anti-GST	NULL
immunoblot	NULL
GST-V14Rho	NULL
|	NULL
a	NULL
«	NULL
«	NULL
Gstth	NULL
-|	NULL
as	NULL
GST	NULL
-~	NULL
|	NULL
«	NULL
aap	NULL
GST	NULL
+	NULL
-	NULL
Jame	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
,	NULL
%	NULL
>	NULL
.	NULL

oo	NULL
tp	NULL
my	NULL
Bp	NULL
A	NULL
,	NULL
°C	NULL
h	NULL
%	NULL
1	NULL
203	NULL
4	NULL
``	NULL
a	NULL
**	NULL
,	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Activated	NULL
Rho	NULL
and	NULL
membrane-targeted	NULL
Rho	NULL
preferentially	NULL
associate	NULL
with	NULL
PKCa	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
20	NULL
pg	NULL
of	NULL
pEBG	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
)	NULL
or	NULL
V14Rho	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
8	NULL
)	NULL
for	NULL
15	NULL
h.	NULL
Cells	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
lysed	NULL
,	NULL
precipitated	NULL
with	NULL
glutathione-Sepharose	NULL
beads	NULL
,	NULL
and	NULL
immunoblotted	NULL
with	NULL
anti-PKC	NULL
antibodies	NULL
(	NULL
A	NULL
)	NULL
and	NULL
anti-GST	NULL
antibody	NULL
(	NULL
B	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
pEBG	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
V14Rho	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
for	NULL
15	NULL
h.	NULL
Cells	NULL
(	NULL
7	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
lysed	NULL
in	NULL
hypotonic	NULL
solution	NULL
and	NULL
fractionated	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Proteins	NULL
that	NULL
precipitated	NULL
with	NULL
glutathione-Sepharose	NULL
beads	NULL
were	NULL
immunoblotted	NULL
with	NULL
anti-PKCa	NULL
antibody	NULL
(	NULL
C	NULL
)	NULL
and	NULL
anti-GST	NULL
antibody	NULL
(	NULL
D	NULL
)	NULL
.	NULL

C	NULL
,	NULL
cytosol	NULL
fraction	NULL
;	NULL
M	NULL
,	NULL
membrane	NULL
particulate	NULL
fraction	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
20	NULL
mg	NULL
of	NULL
pEBG	NULL
,	NULL
wt	NULL
Rho	NULL
,	NULL
V1i4Rho	NULL
,	NULL
N19Rho	NULL
,	NULL
or	NULL
V14Rho-ACAAX	NULL
for	NULL
15	NULL
h.	NULL
Transfected	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
lysed	NULL
,	NULL
and	NULL
glutathi-one	NULL
bead-precipitated	NULL
proteins	NULL
were	NULL
immunoblotted	NULL
with	NULL
anti-PKC	NULL
«	NULL
antibody	NULL
(	NULL
E	NULL
)	NULL
and	NULL
anti-GST	NULL
antibody	NULL
(	NULL
F	NULL
)	NULL
.	NULL

are	NULL
important	NULL
for	NULL
phosphate	NULL
binding	NULL
,	NULL
and	NULL
residues	NULL
35	NULL
to	NULL
40	NULL
of	NULL
Ras	NULL
are	NULL
required	NULL
for	NULL
effector	NULL
binding	NULL
.	NULL

To	NULL
address	NULL
whether	NULL
the	NULL
effector	NULL
domain	NULL
of	NULL
Rho	NULL
regulates	NULL
the	NULL
activated-Rho	NULL
enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
,	NULL
pEBG-V38T/V1l4rho	NULL
,	NULL
pEBG-F39Y/V14rho	NULL
,	NULL
pEBG-E40I/V14rho	NULL
,	NULL
pEBG-N41I/V14rho	NULL
,	NULL
or	NULL
pEBG-T37A/E40I/V14rho	NULL
was	NULL
cotransfected	NULL
with	NULL
pGL2	NULL
(	NULL
-140	NULL
AP-1	NULL
)	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
mutation	NULL
of	NULL
residue	NULL
39	NULL
,	NULL
40	NULL
,	NULL
or	NULL
37	NULL
and	NULL
40	NULL
of	NULL
Rho	NULL
abolished	NULL
activated-Rho-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
following	NULL
PMA	NULL
stimulation	NULL
.	NULL

However	NULL
,	NULL
mutation	NULL
of	NULL
residue	NULL
38	NULL
or	NULL
41	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
activated-Rho-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
expression	NULL
of	NULL
GST-Rho	NULL
fusion	NULL
proteins	NULL
of	NULL
these	NULL
mutants	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
.	NULL

The	NULL
N	NULL
termini	NULL
of	NULL
small	NULL
GTP-binding	NULL
proteins	NULL
are	NULL
important	NULL
for	NULL
GTPase	NULL
activity	NULL
and	NULL
effector	NULL
functions	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
C	NULL
termini	NULL
of	NULL
the	NULL
members	NULL
of	NULL
the	NULL
GTP-binding	NULL
family	NULL
of	NULL
proteins	NULL
possess	NULL
posttranslational	NULL
modification	NULL
sites	NULL
for	NULL
carboxylation	NULL
,	NULL
prenylation	NULL
,	NULL
or	NULL
geranylgeranylation	NULL
(	NULL
12	NULL
,	NULL
53	NULL
,	NULL
54	NULL
)	NULL
.	NULL

Posttranslational	NULL
modifications	NULL
are	NULL
required	NULL
for	NULL
targeting	NULL
the	NULL
small	NULL
G	NULL
proteins	NULL
to	NULL
the	NULL
proper	NULL
membrane	NULL
location	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2C	NULL
and	NULL
E	NULL
,	NULL
membrane-bound	NULL
V14Rho	NULL
strongly	NULL
associated	NULL
with	NULL
PKCa	NULL
;	NULL
removal	NULL
of	NULL
the	NULL
membrane-targeting	NULL
signal	NULL
of	NULL
V14Rho	NULL
diminished	NULL
its	NULL
association	NULL
with	NULL
PKCa	NULL
.	NULL

To	NULL
address	NULL
if	NULL
membrane	NULL
targeting	NULL
of	NULL
V14Rho	NULL
is	NULL
required	NULL
for	NULL
its	NULL
enhancement	NULL
of	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
,	NULL
V14Rho-ACAAX	NULL
was	NULL
transiently	NULL
co	NULL
Rho	NULL
REGULATES	NULL
AP-1	NULL
TRANSCRIPTIONAL	NULL
ACTIVATION	NULL
-	NULL
4989	NULL
transfected	NULL
with	NULL
the	NULL
pGL2	NULL
(	NULL
-140	NULL
AP-1	NULL
)	NULL
luciferase	NULL
reporter	NULL
construct	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
overexpression	NULL
of	NULL
V14Rho-ACAAX	NULL
did	NULL
not	NULL
enhance	NULL
basal	NULL
or	NULL
PMA-stimulated	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
expression	NULL
of	NULL
N19Rho	NULL
did	NULL
not	NULL
potentiate	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

V14Rho-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
is	NULL
independent	NULL
of	NULL
the	NULL
MEK	NULL
pathway	NULL
.	NULL

The	NULL
AP-1	NULL
complex	NULL
is	NULL
comprised	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
Fos	NULL
and	NULL
Jun	NULL
.	NULL

Since	NULL
JunB	NULL
DNA	NULL
binding	NULL
activity	NULL
is	NULL
regulated	NULL
by	NULL
Ras	NULL
,	NULL
we	NULL
addressed	NULL
the	NULL
possibility	NULL
that	NULL
activated	NULL
Ras	NULL
can	NULL
also	NULL
enhance	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
(	NULL
9	NULL
,	NULL
10	NULL
,	NULL
52	NULL
)	NULL
.	NULL

pEBG-V12ras	NULL
and	NULL
pGL2	NULL
(	NULL
-140	NULL
AP-1	NULL
)	NULL
luciferase	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
stimulated	NULL
with	NULL
PMA	NULL
.	NULL

The	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
V12Ras	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
seen	NULL
in	NULL
vector-transfected	NULL
cells	NULL
following	NULL
PMA	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
left	NULL
)	NULL
.	NULL

The	NULL
Ras-MEK-MAPK	NULL
pathway	NULL
links	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
surface	NULL
receptors	NULL
to	NULL
nuclear	NULL
events	NULL
.	NULL

To	NULL
address	NULL
the	NULL
involvement	NULL
of	NULL
MAPK	NULL
in	NULL
V14Rho-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
,	NULL
DN	NULL
MEK	NULL
and	NULL
a	NULL
MEK	NULL
inhibitor	NULL
were	NULL
used	NULL
in	NULL
the	NULL
assay	NULL
.	NULL

The	NULL
pGL2	NULL
(	NULL
-140	NULL
AP-1	NULL
)	NULL
luciferase	NULL
reporter	NULL
construct	NULL
was	NULL
cotransfected	NULL
with	NULL
pEBG	NULL
or	NULL
V14Rho	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
pEBG-DN-MEK	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
stimulated	NULL
with	NULL
PMA	NULL
,	NULL
and	NULL
luciferase	NULL
activities	NULL
were	NULL
determined	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
(	NULL
right	NULL
)	NULL
,	NULL
DN	NULL
MEK	NULL
did	NULL
not	NULL
affect	NULL
V14Rho-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
,	NULL
while	NULL
it	NULL
partially	NULL
blocked	NULL
the	NULL
PMA	NULL
enhancement	NULL
of	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

To	NULL
confirm	NULL
these	NULL
findings	NULL
,	NULL
vector-	NULL
and	NULL
V14Rho-transfected	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
50	NULL
um	NULL
MEK	NULL
inhibitor	NULL
(	NULL
PD98059	NULL
)	NULL
for	NULL
30	NULL
min	NULL
prior	NULL
to	NULL
PMA	NULL
stimulation	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
(	NULL
right	NULL
)	NULL
,	NULL
the	NULL
MEK	NULL
inhibitor	NULL
did	NULL
not	NULL
affect	NULL
V14Rho-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
.	NULL

However	NULL
,	NULL
the	NULL
MEK	NULL
inhibitor	NULL
partially	NULL
blocked	NULL
the	NULL
PMA-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
in	NULL
vector-	NULL
or	NULL
V14Rho-transfected	NULL
cells	NULL
.	NULL

Two	NULL
possible	NULL
interpretations	NULL
of	NULL
these	NULL
results	NULL
are	NULL
(	NULL
i	NULL
)	NULL
the	NULL
MEK	NULL
inhibitor	NULL
blocked	NULL
only	NULL
the	NULL
PMA-dependent	NULL
enhancement	NULL
of	NULL
AP-1	NULL
transcription	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
synergy	NULL
seen	NULL
with	NULL
V14Rho	NULL
plus	NULL
PMA	NULL
partially	NULL
recruits	NULL
the	NULL
MEK	NULL
pathway	NULL
.	NULL

N-PKCa	NULL
blocks	NULL
activated-Rho-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

Our	NULL
observation	NULL
that	NULL
PKCa	NULL
physically	NULL
associated	NULL
with	NULL
Rho	NULL
in	NULL
the	NULL
membrane	NULL
fraction	NULL
of	NULL
cells	NULL
suggested	NULL
a	NULL
role	NULL
for	NULL
this	NULL
interaction	NULL
in	NULL
the	NULL
Rho-induced	NULL
regulation	NULL
of	NULL
AP-1	NULL
activity	NULL
.	NULL

This	NULL
observation	NULL
is	NULL
consistent	NULL
with	NULL
a	NULL
previous	NULL
report	NULL
that	NULL
Rholp	NULL
binds	NULL
the	NULL
N-terminal	NULL
regulatory	NULL
domain	NULL
of	NULL
Pkelp	NULL
in	NULL
S.	NULL
cerevisiae	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
PKCa	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
activated-Rho-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
,	NULL
Myc-tagged	NULL
wt	NULL
PKCa	NULL
and	NULL
pGL2	NULL
(	NULL
-140	NULL
AP-1	NULL
)	NULL
were	NULL
cotransfected	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
coexpression	NULL
of	NULL
PKCa	NULL
and	NULL
V14Rho	NULL
enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
following	NULL
PMA	NULL
stimulation	NULL
.	NULL

To	NULL
further	NULL
address	NULL
if	NULL
Rho	NULL
binding	NULL
to	NULL
PKCa	NULL
affects	NULL
V14Rho-mediated	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
,	NULL
a	NULL
construct	NULL
encoding	NULL
c-Myc-tagged	NULL
N-terminal	NULL
regulatory	NULL
domain	NULL
of	NULL
PKCa	NULL
was	NULL
coexpressed	NULL
with	NULL
activated	NULL
Rho	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Overexpression	NULL
of	NULL
N-PKCa	NULL
blocked	NULL
the	NULL
basal-	NULL
and	NULL
activated-Rho-plus-PMA-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
,	NULL
supporting	NULL
a	NULL
role	NULL
for	NULL
this	NULL
kinase	NULL
in	NULL
mediating	NULL
the	NULL
downstream	NULL
effects	NULL
of	NULL
Rho	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
GST-V14Rho	NULL
were	NULL
expressed	NULL
in	NULL
these	NULL
transfections	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

N-PKCa	NULL
that	NULL
associated	NULL
with	NULL
GST-V14Rho	NULL
was	NULL
detected	NULL
by	NULL
anti-c-Myc	NULL
antibody	NULL
(	NULL
9E10	NULL
)	NULL
immunoblotting	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
.	NULL

DISCUSSION	NULL
Regulation	NULL
of	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

Rho	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
numerous	NULL
biological	NULL
processes	NULL
of	NULL
diverse	NULL
cell	NULL
types	NULL
.	NULL

In	NULL
lymphocytes	NULL
,	NULL
Rho	NULL
has	NULL
been	NULL
proposed	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
lymphocyte	NULL
motility	NULL
and	NULL
adhesion	NULL
(	NULL
28	NULL
,	NULL
50	NULL
)	NULL
,	NULL
thymic	NULL
develop	NULL
4990	NULL
CHANG	NULL
ET	NULL
AL	NULL
.	NULL

30	NULL
-I	NULL
20	NULL
Fold	NULL
AP-1	NULL
(	NULL
-140	NULL
)	NULL
luciferase	NULL
activation	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

B	NULL
Anti-GST	NULL
immunoblot	NULL
GST-Rho	NULL
-	NULL
»	NULL
as	NULL
9	NULL
*~	NULL
.	NULL

'-	NULL
ast	NULL
-	NULL
»	NULL
|	NULL
«	NULL
®	NULL
Co-	NULL
as	NULL
20	NULL
7	NULL
Fold	NULL
(	NULL
-140	NULL
)	NULL
AP-1	NULL
luciferase	NULL
activation	NULL
0	NULL
PMA	NULL
(	NULL
1Ong/mi	NULL
)	NULL
|	NULL
-	NULL
4	NULL
0	NULL
-	NULL
$	NULL
0	NULL
-	NULL
+	NULL
pEBG	NULL
-	NULL
VidRho	NULL
-	NULL
V14Rho	NULL
-ACAAX	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

An	NULL
intact	NULL
effector	NULL
domain	NULL
and	NULL
membrane	NULL
targeting	NULL
of	NULL
V14Rho	NULL
are	NULL
required	NULL
for	NULL
the	NULL
enhancement	NULL
of	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
pEBG	NULL
,	NULL
V14Rho	NULL
,	NULL
V38T/V14Rho	NULL
,	NULL
F39Y/V14Rho	NULL
,	NULL
E40I/V14Rho	NULL
,	NULL
N41I/V14Rho	NULL
,	NULL
T37A/E40I/V14Rho	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
V14Rho-ACAAX	NULL
(	NULL
C	NULL
)	NULL
,	NULL
and	NULL
approximately	NULL
10	NULL
ug	NULL
of	NULL
AP-1	NULL
enhancer	NULL
element	NULL
reporter	NULL
construct	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
7	NULL
h	NULL
,	NULL
and	NULL
AP-1	NULL
enhancer	NULL
clement-driven	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

ment	NULL
(	NULL
17	NULL
,	NULL
20	NULL
)	NULL
,	NULL
and	NULL
cell	NULL
survival	NULL
and	NULL
cytolytic	NULL
function	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Although	NULL
many	NULL
recent	NULL
studies	NULL
have	NULL
focused	NULL
on	NULL
the	NULL
role	NULL
and	NULL
regulation	NULL
of	NULL
Rho	NULL
in	NULL
lymphocytes	NULL
,	NULL
little	NULL
is	NULL
understood	NULL
about	NULL
the	NULL
effector	NULL
mechanisms	NULL
elicited	NULL
by	NULL
Rho	NULL
that	NULL
lead	NULL
to	NULL
these	NULL
terminal	NULL
events	NULL
.	NULL

We	NULL
have	NULL
conducted	NULL
studies	NULL
to	NULL
delineate	NULL
downstream	NULL
effectors	NULL
of	NULL
Rho	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
found	NULL
a	NULL
striking	NULL
effect	NULL
of	NULL
V14Rho	NULL
on	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

This	NULL
result	NULL
is	NULL
consistent	NULL
with	NULL
a	NULL
pivotal	NULL
role	NULL
for	NULL
Rho	NULL
in	NULL
lymphocyte	NULL
signaling	NULL
,	NULL
as	NULL
it	NULL
is	NULL
well	NULL
established	NULL
that	NULL
AP-1	NULL
is	NULL
critically	NULL
involved	NULL
in	NULL
T-cell	NULL
activation	NULL
.	NULL

In	NULL
lymphocytes	NULL
,	NULL
the	NULL
AP-1	NULL
enhancer	NULL
element	NULL
is	NULL
found	NULL
in	NULL
the	NULL
promoters	NULL
of	NULL
genes	NULL
that	NULL
encode	NULL
proteins	NULL
involved	NULL
in	NULL
the	NULL
immune	NULL
functions	NULL
for	NULL
which	NULL
Rho	NULL
has	NULL
also	NULL
been	NULL
impli-cated	NULL
,	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
AP-1	NULL
enhancer	NULL
element	NULL
binds	NULL
transcription	NULL
factors	NULL
of	NULL
the	NULL
Fos	NULL
and	NULL
Jun	NULL
families	NULL
that	NULL
have	NULL
formed	NULL
homodimers	NULL
or	NULL
heterodimers	NULL
prior	NULL
to	NULL
binding	NULL
.	NULL

At	NULL
least	NULL
four	NULL
Fos	NULL
family	NULL
members	NULL
(	NULL
c-Fos	NULL
,	NULL
FosB	NULL
,	NULL
Fra-1	NULL
,	NULL
and	NULL
Fra-2	NULL
)	NULL
and	NULL
four	NULL
Jun	NULL
family	NULL
members	NULL
(	NULL
v-Jun	NULL
,	NULL
c-Jun	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
JunD	NULL
)	NULL
have	NULL
been	NULL
identified	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
Fos	NULL
and	NULL
Jun	NULL
to	NULL
the	NULL
AP-1	NULL
transcription	NULL
element	NULL
of	NULL
the	NULL
IL-2P	NULL
has	NULL
been	NULL
characterized	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
-140	NULL
AP-1	NULL
enhancer	NULL
element	NULL
ablates	NULL
PMA-	NULL
and	NULL
TCR-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

Our	NULL
data	NULL
show	NULL
that	NULL
Rho	NULL
enhanced	NULL
-140	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
,	NULL
suggesting	NULL
that	NULL
activated	NULL
Rho	NULL
may	NULL
activate	NULL
transcription	NULL
factors	NULL
of	NULL
the	NULL
Fos	NULL
and	NULL
Jun	NULL
families	NULL
.	NULL

These	NULL
data	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
those	NULL
of	NULL
others	NULL
(	NULL
21	NULL
)	NULL
,	NULL
which	NULL
demonstrated	NULL
that	NULL
activated	NULL
Rho	NULL
enhanced	NULL
c-fos	NULL
transcriptional	NULL
activity	NULL
.	NULL

The	NULL
transcription	NULL
of	NULL
c-fos	NULL
is	NULL
regulated	NULL
through	NULL
ternary	NULL
complex	NULL
factor	NULL
(	NULL
TCF	NULL
)	NULL
and	NULL
SRF	NULL
.	NULL

Binding	NULL
of	NULL
TCF	NULL
and	NULL
SRF	NULL
to	NULL
the	NULL
serum	NULL
response	NULL
element	NULL
(	NULL
SRE	NULL
)	NULL
coordinately	NULL
enhances	NULL
c-fos	NULL
transcriptional	NULL
activation	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
revealed	NULL
that	NULL
transcription	NULL
of	NULL
c-fos	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
SRF	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TCF	NULL
activation	NULL
.	NULL

SRF	NULL
is	NULL
activated	NULL
through	NULL
a	NULL
Rho-dependent	NULL
pathway	NULL
.	NULL

Further	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
PMA	NULL
enhanced	NULL
SRF	NULL
phosphorylation	NULL
and	NULL
TCF	NULL
binding	NULL
to	NULL
SRE	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
consistent	NULL
with	NULL
our	NULL
results	NULL
that	NULL
PMA	NULL
and	NULL
activated	NULL
Rho	NULL
synergize	NULL
to	NULL
enhance	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
.	NULL

Association	NULL
of	NULL
PKCa	NULL
with	NULL
Rho	NULL
.	NULL

To	NULL
determine	NULL
potential	NULL
upstream	NULL
regulators	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
Rho	NULL
on	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
,	NULL
we	NULL
have	NULL
dissected	NULL
kinase	NULL
pathways	NULL
critical	NULL
in	NULL
T-cell	NULL
signaling	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
kinase	NULL
activities	NULL
of	NULL
Erk	NULL
,	NULL
JNK	NULL
,	NULL
and	NULL
p38	NULL
MAPKs	NULL
were	NULL
unaffected	NULL
by	NULL
coexpression	NULL
of	NULL
V14Rho	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
previously	NULL
published	NULL
findings	NULL
in	NULL
other	NULL
labs	NULL
(	NULL
21	NULL
,	NULL
30	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
inability	NULL
of	NULL
DN	NULL
MEK	NULL
or	NULL
a	NULL
MEK	NULL
inhibitor	NULL
to	NULL
block	NULL
the	NULL
Rho-mediated	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
suggested	NULL
that	NULL
MAPK	NULL
is	NULL
not	NULL
in	NULL
Vou	NULL
.	NULL

18	NULL
,	NULL
1998	NULL
Rho	NULL
REGULATES	NULL
AP-1	NULL
TRANSCRIPTIONAL	NULL
ACTIVATION	NULL
-	NULL
4991	NULL
40	NULL
20	NULL
30	NULL
7	NULL
20	NULL
Fold	NULL
(	NULL
-140	NULL
)	NULL
AP-1	NULL
luciferase	NULL
activation	NULL
Fold	NULL
(	NULL
-140	NULL
)	NULL
AP-1	NULL
luciferase	NULL
activation	NULL
0	NULL
0-	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
-	NULL
L	NULL
p	NULL
L2	NULL
p	NULL
coop	NULL
o-	NULL
go-	NULL
£	NULL
PMA	NULL
(	NULL
10ng/m	NULL
!	NULL
)	NULL

=o	NULL
doo	NULL
o=	NULL
oB	NULL
o=	NULL
o	NULL
Mek	NULL
Inh	NULL
(	NULL
50	NULL
uM	NULL
)	NULL
+o+	NULL
+	NULL
pEBG	NULL
__	NULL
V1i2Ras	NULL
-	NULL
VidRho	NULL
DN	NULL
Mek	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
+	NULL
+	NULL
+o	NULL
+	NULL
>	NULL
pEBG	NULL
V14Rho	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

V12Ras	NULL
does	NULL
not	NULL
enhance	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
,	NULL
and	NULL
DN	NULL
MEK	NULL
or	NULL
MEK	NULL
inhibitor	NULL
does	NULL
not	NULL
block	NULL
activated	NULL
Rho-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
pEBG	NULL
,	NULL
10	NULL
pg	NULL
of	NULL
pEBG-V12ras	NULL
,	NULL
10	NULL
pg	NULL
of	NULL
DN	NULL
MEK	NULL
,	NULL
and	NULL
10	NULL
pg	NULL
of	NULL
V14Rho	NULL
,	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
as	NULL
indicated	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
2	NULL
ug	NULL
of	NULL
reporter	NULL
constructs	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

.	NULL

To	NULL
assay	NULL
the	NULL
effect	NULL
of	NULL
MEK	NULL
inhibitor	NULL
on	NULL
V14Rho-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
,	NULL
MEK	NULL
inhibitor	NULL
was	NULL
added	NULL
30	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
PMA	NULL
.	NULL

AP-1-driven	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

volved	NULL
in	NULL
this	NULL
pathway	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
right	NULL
)	NULL
.	NULL

However	NULL
,	NULL
DN	NULL
MEK	NULL
and	NULL
A	NULL
series	NULL
of	NULL
experiments	NULL
demonstrated	NULL
that	NULL
members	NULL
of	NULL
the	NULL
the	NULL
MEK	NULL
inhibitor	NULL
could	NULL
partially	NULL
block	NULL
the	NULL
V14Rho-plus-	NULL
PKC	NULL
family	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
T	NULL
cell-activation	NULL
.	NULL

Binding	NULL
PMA-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
,	NULL
suggesting	NULL
of	NULL
DAG	NULL
or	NULL
the	NULL
DAG	NULL
analog	NULL
PMA	NULL
to	NULL
PKCs	NULL
and	NULL
targeting	NULL
of	NULL
that	NULL
DN	NULL
MEK	NULL
and	NULL
the	NULL
MEK	NULL
inhibitor	NULL
specifically	NULL
inhibited	NULL
the	NULL
PKC	NULL
's	NULL
to	NULL
the	NULL
membrane	NULL
stimulate	NULL
PKC	NULL
kinase	NULL
activity	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Stud-PMA-induced	NULL
MAPK	NULL
activation	NULL
that	NULL
leads	NULL
to	NULL
AP-1	NULL
induction	NULL
.	NULL

ies	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
small	NULL
GTP-binding	NULL
protein	NULL
,	NULL
20	NULL
Fold	NULL
AP1	NULL
(	NULL
-140	NULL
)	NULL
luciferase	NULL
activation	NULL
Fold	NULL
(	NULL
140	NULL
)	NULL
AP-1	NULL
luciferase	NULL
activation	NULL
a	NULL
j	NULL
PMA	NULL
(	NULL
1O0ng/ml	NULL
)	NULL
-	NULL
_+	NULL
~	NULL
o	NULL
+	NULL
-	NULL
+	NULL
-	NULL
__+	NULL
pEBG	NULL
_	NULL
VidRho	NULL
-	NULL
pEBG+	NULL
VidRho+	NULL
o	NULL
|	NULL
.	NULL

wiPKCa	NULL
-	NULL
wiPKCo	NULL
:	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
oce	NULL
pEBG+	NULL
VidRho	NULL
V14Rho+	NULL
N-PKCo	NULL
:	NULL
N-PKCo	NULL
:	NULL
C.	NULL
Anti-GST	NULL
immunoblot	NULL
1	NULL
2	NULL
D	NULL
Anti-c-Myc	NULL
immunoblot	NULL
c-Myc	NULL
epitope	NULL
_	NULL
,	NULL
,	NULL
[	NULL
Z	NULL
]	NULL
tagged	NULL
N-PKCa	NULL
1	NULL
2	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Coexpression	NULL
of	NULL
wt	NULL
PKCa	NULL
augments	NULL
V1i4Rho-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
,	NULL
while	NULL
coexpression	NULL
of	NULL
N-PKCa	NULL
blocks	NULL
activated-Rho-plus-PMA-enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
reporter	NULL
construct	NULL
and	NULL
10	NULL
ug	NULL
of	NULL
V14Rho	NULL
and/or	NULL
pEBB-wt	NULL
PKCa	NULL
(	NULL
A	NULL
)	NULL
or	NULL
10	NULL
ug	NULL
of	NULL
V14Rho	NULL
plus	NULL
10	NULL
g	NULL
of	NULL
pEBB	NULL
or	NULL
a	NULL
construct	NULL
encoding	NULL
N-PKCa	NULL
«	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
7	NULL
h.	NULL
AP-1	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
V14Rho	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
-	NULL
and	NULL
N-PKCa	NULL
construct	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
-transfected	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
lysed	NULL
,	NULL
immunoprecipitated	NULL
with	NULL
glutathione-Sepharose	NULL
beads	NULL
,	NULL
and	NULL
immunoblotted	NULL
with	NULL
anti-GST	NULL
(	NULL
C	NULL
)	NULL
and	NULL
anti-c-Myc	NULL
(	NULL
9E10	NULL
)	NULL
(	NULL
D	NULL
)	NULL
antibodies	NULL
.	NULL

4992	NULL
CHANG	NULL
ET	NULL
AL	NULL
.	NULL

Rholp	NULL
,	NULL
binds	NULL
to	NULL
the	NULL
N-terminal	NULL
pseudosubstrate	NULL
and	NULL
C1	NULL
domains	NULL
of	NULL
Pkelp	NULL
and	NULL
activates	NULL
its	NULL
kinase	NULL
activity	NULL
(	NULL
25	NULL
)	NULL
in	NULL
S.	NULL
cerevisiae	NULL
(	NULL
37	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
activated	NULL
Rho	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
associate	NULL
with	NULL
PKN	NULL
(	NULL
4	NULL
)	NULL
,	NULL
(	NULL
15	NULL
)	NULL
,	NULL
and	NULL
Rho	NULL
kinase	NULL
(	NULL
3	NULL
)	NULL
;	NULL
however	NULL
,	NULL
the	NULL
roles	NULL
of	NULL
these	NULL
associations	NULL
in	NULL
Rho-dependent	NULL
function	NULL
remain	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

In	NULL
studies	NULL
reported	NULL
here	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
Rho	NULL
associates	NULL
with	NULL
PKCa	NULL
in	NULL
vivo	NULL
and	NULL
that	NULL
membrane	NULL
association	NULL
and	NULL
residues	NULL
within	NULL
the	NULL
effector	NULL
domain	NULL
of	NULL
Rho	NULL
are	NULL
required	NULL
for	NULL
maximal	NULL
enhancement	NULL
of	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
.	NULL

The	NULL
observations	NULL
that	NULL
coexpression	NULL
of	NULL
activated	NULL
Rho	NULL
and	NULL
wt	NULL
PKCa	NULL
enhanced	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
and	NULL
N-PKCa	NULL
inhibited	NULL
Rho	NULL
signaling	NULL
underscore	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
association	NULL
of	NULL
these	NULL
proteins	NULL
and	NULL
support	NULL
a	NULL
role	NULL
for	NULL
PKCa	NULL
in	NULL
vivo	NULL
.	NULL

A	NULL
previous	NULL
report	NULL
(	NULL
6	NULL
)	NULL
described	NULL
an	NULL
effect	NULL
of	NULL
PKCO	NULL
on	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
.	NULL

In	NULL
that	NULL
study	NULL
,	NULL
the	NULL
authors	NULL
were	NULL
unable	NULL
to	NULL
detect	NULL
an	NULL
effect	NULL
of	NULL
PKCa	NULL
on	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
in	NULL
assays	NULL
using	NULL
an	NULL
AP-1	NULL
sequence	NULL
derived	NULL
from	NULL
the	NULL
collagenase	NULL
promoter	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
the	NULL
AP-1	NULL
site	NULL
derived	NULL
from	NULL
the	NULL
-140	NULL
region	NULL
of	NULL
the	NULL
IL-2P	NULL
was	NULL
responsive	NULL
to	NULL
activated	NULL
Rho	NULL
,	NULL
while	NULL
other	NULL
enhancer	NULL
elements	NULL
containing	NULL
AP-1	NULL
sites	NULL
were	NULL
unaffected	NULL
,	NULL
indicating	NULL
a	NULL
high	NULL
level	NULL
of	NULL
discrimination	NULL
in	NULL
the	NULL
downstream	NULL
effects	NULL
elicited	NULL
by	NULL
activated	NULL
Rho	NULL
.	NULL

Roles	NULL
for	NULL
several	NULL
other	NULL
members	NULL
of	NULL
the	NULL
PKC	NULL
family	NULL
,	NULL
including	NULL
PKC	NULL
,	NULL
PKC	NULL
{	NULL
,	NULL
PKCn	NULL
,	NULL
and	NULL
PKCA	NULL
(	NULL
22	NULL
,	NULL
24	NULL
,	NULL
49	NULL
)	NULL
,	NULL
in	NULL
transcriptional	NULL
activation	NULL
have	NULL
also	NULL
been	NULL
described	NULL
.	NULL

The	NULL
association	NULL
of	NULL
PKCa	NULL
with	NULL
Rho	NULL
and	NULL
their	NULL
mutual	NULL
involvement	NULL
in	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
provides	NULL
one	NULL
link	NULL
in	NULL
the	NULL
elucidation	NULL
of	NULL
the	NULL
signal	NULL
transduction	NULL
machinery	NULL
that	NULL
regulates	NULL
nuclear	NULL
events	NULL
.	NULL

It	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
if	NULL
the	NULL
association	NULL
between	NULL
PKCa	NULL
and	NULL
Rho	NULL
is	NULL
direct	NULL
or	NULL
indirect	NULL
.	NULL

In	NULL
our	NULL
preliminary	NULL
studies	NULL
,	NULL
we	NULL
have	NULL
been	NULL
unable	NULL
to	NULL
detect	NULL
a	NULL
direct	NULL
physical	NULL
interaction	NULL
between	NULL
these	NULL
two	NULL
proteins	NULL
by	NULL
far-Western	NULL
analysis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
association	NULL
requires	NULL
the	NULL
cooperative	NULL
interaction	NULL
with	NULL
other	NULL
molecules	NULL
or	NULL
the	NULL
native	NULL
conformation	NULL
of	NULL
PKCa	NULL
.	NULL

There	NULL
are	NULL
many	NULL
unanswered	NULL
questions	NULL
as	NULL
to	NULL
the	NULL
immediate	NULL
biochemical	NULL
effects	NULL
that	NULL
this	NULL
interaction	NULL
in-duces	NULL
.	NULL

For	NULL
example	NULL
,	NULL
does	NULL
overexpression	NULL
of	NULL
activated	NULL
Rho	NULL
regulate	NULL
the	NULL
kinase	NULL
activity	NULL
of	NULL
PKCa	NULL
?	NULL

Since	NULL
we	NULL
were	NULL
able	NULL
to	NULL
detect	NULL
this	NULL
association	NULL
only	NULL
in	NULL
the	NULL
membrane	NULL
fraction	NULL
of	NULL
cells	NULL
,	NULL
it	NULL
seems	NULL
likely	NULL
that	NULL
the	NULL
PKCa	NULL
complexed	NULL
with	NULL
Rho	NULL
is	NULL
in	NULL
an	NULL
activated	NULL
state	NULL
,	NULL
as	NULL
previous	NULL
studies	NULL
have	NULL
indicated	NULL
that	NULL
translocation	NULL
of	NULL
PKCa	NULL
to	NULL
the	NULL
membrane	NULL
correlates	NULL
with	NULL
its	NULL
activation	NULL
(	NULL
16	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
could	NULL
PKCa	NULL
modulate	NULL
Rho	NULL
activity	NULL
in	NULL
the	NULL
cell	NULL
through	NULL
direct	NULL
phosphorylation	NULL
or	NULL
indirectly	NULL
by	NULL
phosphorylation	NULL
of	NULL
a	NULL
GEF	NULL
,	NULL
GDI	NULL
,	NULL
GAP	NULL
,	NULL
or	NULL
other	NULL
intermediate	NULL
molecule	NULL
?	NULL

Identification	NULL
of	NULL
the	NULL
specific	NULL
gene	NULL
(	NULL
s	NULL
)	NULL
regulated	NULL
by	NULL
this	NULL
mode	NULL
of	NULL
AP-1	NULL
activation	NULL
will	NULL
indicate	NULL
which	NULL
aspect	NULL
(	NULL
s	NULL
)	NULL
of	NULL
immune	NULL
function	NULL
is	NULL
dependent	NULL
on	NULL
this	NULL
interaction	NULL
and	NULL
its	NULL
downstream	NULL
ef-fects	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
grant	NULL
Al-17258	NULL
to	NULL
S.J.B	NULL
.	NULL

J.C.P	NULL
.	NULL

is	NULL
supported	NULL
by	NULL
an	NULL
NRSA	NULL
fellowship	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
and	NULL
S.S.	NULL
is	NULL
supported	NULL
by	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Cancer	NULL
Research	NULL
Institute	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Alberts	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
O.	NULL
Geneste	NULL
,	NULL
and	NULL
R.	NULL
Treisman	NULL
.	NULL

1998	NULL
.	NULL

Activation	NULL
of	NULL
SRF-regulated	NULL
chromosomal	NULL
templates	NULL
by	NULL
Rho-family	NULL
GTPases	NULL
requires	NULL
a	NULL
signal	NULL
that	NULL
also	NULL
induces	NULL
H4	NULL
hyperacetylation	NULL
.	NULL

Cell	NULL
92:475-487	NULL
.	NULL

2	NULL
.	NULL

Altman	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
I.	NULL
Mally	NULL
,	NULL
and	NULL
N.	NULL
Isakov	NULL
.	NULL

1992	NULL
.	NULL

Phorbol	NULL
ester	NULL
synergizes	NULL
with	NULL
Ca2+	NULL
ionophore	NULL
in	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
alpha	NULL
and	NULL
PKC	NULL
beta	NULL
isoenzymes	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
and	NULL
in	NULL
induction	NULL
of	NULL
related	NULL
cellular	NULL
functions	NULL
.	NULL

Immunology	NULL
76:465-471	NULL
.	NULL

3	NULL
.	NULL

Amano	NULL
,	NULL
M.	NULL
,	NULL
K.	NULL
Chibara	NULL
,	NULL
K.	NULL
Kimura	NULL
,	NULL
Y.	NULL
Fukata	NULL
,	NULL
N.	NULL
Nakamura	NULL
,	NULL
Y.	NULL
Matsuura	NULL
,	NULL
and	NULL
K.	NULL
Kaibuchi	NULL
.	NULL

1997	NULL
.	NULL

Formation	NULL
of	NULL
actin	NULL
stress	NULL
fibers	NULL
and	NULL
focal	NULL
adhesions	NULL
enhanced	NULL
by	NULL
Rho-kinase	NULL
.	NULL

Science	NULL
275:1308-1311	NULL
.	NULL

4	NULL
.	NULL

Amano	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Mukai	NULL
,	NULL
Y.	NULL
Ono	NULL
,	NULL
K.	NULL
Chibara	NULL
,	NULL
T.	NULL
Matsui	NULL
,	NULL
Y.	NULL
Hamajima	NULL
,	NULL
K.	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

Okawa	NULL
,	NULL
A.	NULL
Iwamatsu	NULL
,	NULL
and	NULL
K.	NULL
Kaibuchi	NULL
.	NULL

1996	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
putative	NULL
target	NULL
for	NULL
Rho	NULL
as	NULL
the	NULL
serine-threonine	NULL
kinase	NULL
protein	NULL
kinase	NULL
N.	NULL
Science	NULL
271	NULL
:	NULL
648-650.	NULL
.	NULL

Aramburu	NULL
,	NULL
J.	NULL
,	NULL
L.	NULL
Azzoni	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
B.	NULL
Perussia	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
nuclear	NULL
factors	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
NFATp	NULL
and	NULL
NFATc	NULL
,	NULL
in	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
:	NULL
regulation	NULL
upon	NULL
CD16	NULL
ligand	NULL
binding	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:801-810.	NULL
.	NULL

Baier-Bitterlich	NULL
,	NULL
G.	NULL
,	NULL
F.	NULL
Uberall	NULL
,	NULL
B.	NULL
Bauer	NULL
,	NULL
F.	NULL
Fresser	NULL
,	NULL
H.	NULL
Wachter	NULL
,	NULL
H.	NULL
Gru-	NULL
nicke	NULL
,	NULL
G.	NULL
Utermann	NULL
,	NULL
A.	NULL
Altman	NULL
,	NULL
and	NULL
G.	NULL
Baier	NULL
.	NULL

1996	NULL
.	NULL

Protein	NULL
kinase	NULL
C-theta	NULL
isoenzyme	NULL
selective	NULL
stimulation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
complex	NULL
AP-1	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:1842-1850.	NULL
.	NULL

Barfod	NULL
,	NULL
E.	NULL
T.	NULL
,	NULL
Y.	NULL
Zheng	NULL
,	NULL
W.	NULL
J.	NULL
Kuang	NULL
,	NULL
M.	NULL
J.	NULL
Hart	NULL
,	NULL
T.	NULL
Evans	NULL
,	NULL
R.	NULL
A.	NULL
Cerione	NULL
,	NULL
and	NULL
A.	NULL
Ashkenazi	NULL
.	NULL

1993	NULL
.	NULL

Cloning	NULL
and	NULL
expression	NULL
of	NULL
a	NULL
human	NULL
CDC42	NULL
GTPase-activating	NULL
protein	NULL
reveals	NULL
a	NULL
functional	NULL
SH3-binding	NULL
domain	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:26059-26062.	NULL
.	NULL

Chang	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
S.	NULL
Gill	NULL
,	NULL
J.	NULL
Settleman	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Parsons	NULL
.	NULL

1995.	NULL
c-Src	NULL
regulates	NULL
the	NULL
simultancous	NULL
rearrangement	NULL
of	NULL
actin	NULL
cytoskeleton	NULL
,	NULL
p190RhoGAP	NULL
,	NULL
and	NULL
p120RasGAP	NULL
following	NULL
epidermal	NULL
growth	NULL
factor	NULL
stimulation	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

130:355-368.	NULL
.	NULL

Chauhan	NULL
,	NULL
D.	NULL
,	NULL
S.	NULL
M.	NULL
Kharbanda	NULL
,	NULL
E.	NULL
Rubin	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Barut	NULL
,	NULL
A.	NULL
Mohrbacher	NULL
,	NULL
D.	NULL
W.	NULL
Kufe	NULL
,	NULL
and	NULL
K.	NULL
C.	NULL
Anderson	NULL
.	NULL

1993	NULL
.	NULL

Regulation	NULL
of	NULL
c-jun	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Blood	NULL
81:1540-1548	NULL
.	NULL

D'Ambrosio	NULL
,	NULL
D.	NULL
,	NULL
D.	NULL
A.	NULL
Cantrell	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
A.	NULL
Santoni	NULL
,	NULL
and	NULL
R.	NULL
Testi	NULL
.	NULL

1994	NULL
.	NULL

Involvement	NULL
of	NULL
p21ras	NULL
activation	NULL
in	NULL
T	NULL
cell	NULL
CD69	NULL
expression	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24:616-620	NULL
.	NULL

Diekmann	NULL
,	NULL
D.	NULL
,	NULL
S.	NULL
Brill	NULL
,	NULL
M.	NULL
D.	NULL
Garrett	NULL
,	NULL
N.	NULL
Totty	NULL
,	NULL
J.	NULL
Hsuan	NULL
,	NULL
C.	NULL
Monfries	NULL
,	NULL
C.	NULL
Hall	NULL
,	NULL
L.	NULL
Lim	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Hall	NULL
.	NULL

1991	NULL
.	NULL

Ber	NULL
encodes	NULL
a	NULL
GTPase-activating	NULL
protein	NULL
for	NULL
p2lrac	NULL
.	NULL

Nature	NULL
351:400-402	NULL
.	NULL

Foster	NULL
,	NULL
R.	NULL
,	NULL
K.	NULL
Q.	NULL
Hu	NULL
,	NULL
Y.	NULL
Lu	NULL
,	NULL
K.	NULL
M.	NULL
Nolan	NULL
,	NULL
J.	NULL
Thissen	NULL
,	NULL
and	NULL
J.	NULL
Settleman	NULL
.	NULL

1996	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
novel	NULL
human	NULL
Rho	NULL
protein	NULL
with	NULL
unusual	NULL
properties	NULL
:	NULL
GTPase	NULL
deficiency	NULL
and	NULL
in	NULL
vivo	NULL
farnesylation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:2689-2699	NULL
.	NULL

Frantz	NULL
,	NULL
B.	NULL
,	NULL
E.	NULL
C.	NULL
Nordby	NULL
,	NULL
G.	NULL
Bren	NULL
,	NULL
N.	NULL
Steffan	NULL
,	NULL
C.	NULL
V.	NULL
Paya	NULL
,	NULL
R.	NULL
L.	NULL
Kincaid	NULL
,	NULL
M.	NULL
J.	NULL
Tocci	NULL
,	NULL
S.	NULL
J.	NULL
O'Keefe	NULL
,	NULL
and	NULL
E.	NULL
A.	NULL
O'Neill	NULL
.	NULL

1994	NULL
.	NULL

Calcineurin	NULL
acts	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
inactivate	NULL
I	NULL
kappa	NULL
B/MAD3	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
NF-kappa	NULL
B.	NULL
EMBO	NULL
J	NULL
.	NULL

13:861-870	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
M.	NULL
E.	NULL
Newton	NULL
,	NULL
A.	NULL
Weiss	NULL
,	NULL
M.	NULL
P.	NULL
Duyao	NULL
,	NULL
D.	NULL
J.	NULL
Kessler	NULL
,	NULL
D.	NULL
B.	NULL
Spicer	NULL
,	NULL
and	NULL
G.	NULL
E.	NULL
Sonenshein	NULL
.	NULL

1992	NULL
.	NULL

CD28	NULL
and	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
signal	NULL
transduction	NULL
coordinately	NULL
regulate	NULL
interleukin	NULL
2	NULL
gene	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
superantigen	NULL
stimulation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:1131-1134	NULL
.	NULL

Fujisawa	NULL
,	NULL
K.	NULL
,	NULL
A.	NULL
Fujita	NULL
,	NULL
T.	NULL
Ishizaki	NULL
,	NULL
Y.	NULL
Saito	NULL
,	NULL
and	NULL
S.	NULL
Narumiya	NULL
.	NULL

1996	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
Rho-binding	NULL
domain	NULL
of	NULL
p160ROCK	NULL
,	NULL
a	NULL
Rho-associated	NULL
coiled-coil	NULL
containing	NULL
protein	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:23022-23028	NULL
.	NULL

Fulop	NULL
,	NULL
T.	NULL
,	NULL
Jr.	NULL
,	NULL
C.	NULL
Leblanc	NULL
,	NULL
G.	NULL
Lacombe	NULL
,	NULL
and	NULL
G.	NULL
Dupuis	NULL
.	NULL

1995	NULL
.	NULL

Cellular	NULL
distribution	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
isozymes	NULL
in	NULL
CD3-mediated	NULL
stimulation	NULL
of	NULL
human	NULL
T	NULL
lymphocytes	NULL
with	NULL
aging	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

375:69-74	NULL
.	NULL

Galandrini	NULL
,	NULL
R.	NULL
,	NULL
S.	NULL
W.	NULL
Henning	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Cantrell	NULL
.	NULL

1997	NULL
.	NULL

Different	NULL
functions	NULL
of	NULL
the	NULL
GTPase	NULL
Rho	NULL
in	NULL
prothymocytes	NULL
and	NULL
late	NULL
pre-T	NULL
cells	NULL
.	NULL

Immunity	NULL
7:163-174	NULL
.	NULL

Hall	NULL
,	NULL
A	NULL
.	NULL

1992	NULL
.	NULL

Ras-related	NULL
GTPases	NULL
and	NULL
the	NULL
cytoskeleton	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Cell	NULL
3	NULL
:	NULL
475-479	NULL
.	NULL

Hall	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
F.	NULL
Paterson	NULL
,	NULL
P.	NULL
Adamson	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Ridley	NULL
.	NULL

1993	NULL
.	NULL

Cellular	NULL
responses	NULL
regulated	NULL
by	NULL
rho-related	NULL
small	NULL
GTP-binding	NULL
proteins	NULL
.	NULL

Philos	NULL
.	NULL

Trans	NULL
.	NULL

R.	NULL
Soc	NULL
.	NULL

Lond	NULL
.	NULL

Ser	NULL
.	NULL

B	NULL
340:267-271	NULL
.	NULL

Henning	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
R.	NULL
Galandrini	NULL
,	NULL
A	NULL
.	NULL

Hall	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Cantrell	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
GTPase	NULL
Rho	NULL
has	NULL
a	NULL
critical	NULL
regulatory	NULL
role	NULL
in	NULL
thymus	NULL
development	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

16:2397-2407	NULL
.	NULL

Hill	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
J.	NULL
Wynne	NULL
,	NULL
and	NULL
R.	NULL
Treisman	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
Rho	NULL
family	NULL
GTPases	NULL
RhoA	NULL
,	NULL
Racl	NULL
,	NULL
and	NULL
CDC42Hs	NULL
regulate	NULL
transcriptional	NULL
activation	NULL
by	NULL
SRF	NULL
.	NULL

Cell	NULL
81:1159-1170	NULL
.	NULL

Hirano	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Hirai	NULL
,	NULL
K.	NULL
Mizuno	NULL
,	NULL
S.	NULL
Osada	NULL
,	NULL
M.	NULL
Hosaka	NULL
,	NULL
and	NULL
S.	NULL
Ohno	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
protein	NULL
kinase	NULL
C	NULL
isozyme	NULL
,	NULL
nPKC	NULL
epsilon	NULL
,	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
NF-kappa	NULL
B	NULL
by	NULL
12-O-tetradecanoylphorbol-l3-acetate	NULL
(	NULL
TPA	NULL
)	NULL
in	NULL
rat	NULL
3Y¥1	NULL
fibroblasts	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

206:429-436	NULL
.	NULL

Horii	NULL
,	NULL
Y.	NULL
,	NULL
J.	NULL
F.	NULL
Beeler	NULL
,	NULL
K.	NULL
Sakaguchi	NULL
,	NULL
M.	NULL
Tachibana	NULL
,	NULL
and	NULL
T.	NULL
Miki	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
novel	NULL
oncogene	NULL
,	NULL
ost	NULL
,	NULL
encodes	NULL
a	NULL
guanine	NULL
nucleotide	NULL
exchange	NULL
factor	NULL
that	NULL
potentially	NULL
links	NULL
Rho	NULL
and	NULL
Rac	NULL
signaling	NULL
pathways	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:4776-4786	NULL
.	NULL

Huang	NULL
,	NULL
C.	NULL
,	NULL
W.	NULL
Ma	NULL
,	NULL
and	NULL
Z.	NULL
Dong	NULL
.	NULL

1997	NULL
.	NULL

Signal	NULL
transduction	NULL
through	NULL
atypical	NULL
PKCs	NULL
,	NULL
but	NULL
not	NULL
the	NULL
EGF	NULL
receptor	NULL
,	NULL
is	NULL
necessary	NULL
for	NULL
UVC-induced	NULL
AP-1	NULL
activation	NULL
in	NULL
immortal	NULL
murine	NULL
cells	NULL
.	NULL

Oncogene	NULL
14:1945-1954.	NULL
.	NULL

Kamada	NULL
,	NULL
Y.	NULL
,	NULL
H.	NULL
Qadota	NULL
,	NULL
C.	NULL
P.	NULL
Python	NULL
,	NULL
Y.	NULL
Anraku	NULL
,	NULL
Y.	NULL
Ohya	NULL
,	NULL
and	NULL
D.	NULL
E.	NULL
Levin	NULL
.	NULL

1996	NULL
.	NULL

Activation	NULL
of	NULL
yeast	NULL
protein	NULL
kinase	NULL
C	NULL
by	NULL
Rho1	NULL
GTPase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:9193-9196	NULL
.	NULL

Khosravi-Far	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
A.	NULL
Solski	NULL
,	NULL
G.	NULL
J.	NULL
Clark	NULL
,	NULL
M.	NULL
S.	NULL
Kinch	NULL
,	NULL
and	NULL
C.	NULL
J	NULL
.	NULL

Der	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
Rac	NULL
,	NULL
RhoA	NULL
,	NULL
and	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
is	NULL
required	NULL
for	NULL
Ras	NULL
transformation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:6443-6453	NULL
.	NULL

Lang	NULL
,	NULL
P.	NULL
,	NULL
L.	NULL
Guizani	NULL
,	NULL
I.	NULL
Vitte-Mony	NULL
,	NULL
R.	NULL
Stancou	NULL
,	NULL
O.	NULL
Dorseuil	NULL
,	NULL
G.	NULL
Gacon	NULL
,	NULL
and	NULL
J.	NULL
Bertoglio	NULL
.	NULL

1992	NULL
.	NULL

ADP-ribosylation	NULL
of	NULL
the	NULL
ras-related	NULL
,	NULL
GTP-binding	NULL
protein	NULL
RhoA	NULL
inhibits	NULL
lymphocyte-mediated	NULL
cytotoxicity	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267:11677-11680	NULL
.	NULL

Laudanna	NULL
,	NULL
C.	NULL
,	NULL
J.	NULL
J.	NULL
Campbell	NULL
,	NULL
and	NULL
E.	NULL
C.	NULL
Butcher	NULL
.	NULL

1996	NULL
.	NULL

Role	NULL
of	NULL
Rho	NULL
in	NULL
chemoattractant-activated	NULL
leukocyte	NULL
adhesion	NULL
through	NULL
integrins	NULL
.	NULL

Science	NULL
271	NULL
:	NULL
981-983	NULL
.	NULL

Vou	NULL
.	NULL

18	NULL
,	NULL
1998	NULL
29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

Michiels	NULL
,	NULL
F.	NULL
,	NULL
G.	NULL
G.	NULL
Habets	NULL
,	NULL
J.	NULL
C.	NULL
Stam	NULL
,	NULL
R.	NULL
A.	NULL
van	NULL
der	NULL
Kammen	NULL
,	NULL
and	NULL
J.	NULL
G.	NULL
Collard	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
role	NULL
for	NULL
Rac	NULL
in	NULL
Tiam1-induced	NULL
membrane	NULL
ruffling	NULL
and	NULL
invasion	NULL
.	NULL

Nature	NULL
375:338-340	NULL
.	NULL

Minden	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Lin	NULL
,	NULL
F.	NULL
X.	NULL
Claret	NULL
,	NULL
A.	NULL
Abo	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1995	NULL
.	NULL

Selective	NULL
activation	NULL
of	NULL
the	NULL
JNK	NULL
signaling	NULL
cascade	NULL
and	NULL
c-Jun	NULL
transcriptional	NULL
activity	NULL
by	NULL
the	NULL
small	NULL
GTPases	NULL
Rac	NULL
and	NULL
Cdce42Hs	NULL
.	NULL

Cell	NULL
81:1147-1157	NULL
.	NULL

Mischak	NULL
,	NULL
H.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Goodnight	NULL
,	NULL
W.	NULL
Kolch	NULL
,	NULL
G.	NULL
Martiny-Baron	NULL
,	NULL
C.	NULL
Schaechtle	NULL
,	NULL
M.	NULL
G.	NULL
Kazanietz	NULL
,	NULL
P.	NULL
M.	NULL
Blumberg	NULL
,	NULL
J.	NULL
H.	NULL
Pierce	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Mushinski	NULL
.	NULL

1993	NULL
.	NULL

Overexpression	NULL
of	NULL
protein	NULL
kinase	NULL
C-delta	NULL
and	NULL
-epsilon	NULL
in	NULL
NIH	NULL
3T3	NULL
cells	NULL
induces	NULL
opposite	NULL
effects	NULL
on	NULL
growth	NULL
,	NULL
morphology	NULL
,	NULL
anchorage	NULL
dependence	NULL
,	NULL
and	NULL
tumorigenicity	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:6090-6096	NULL
.	NULL

Newton	NULL
,	NULL
A.	NULL
C.	NULL
1995	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
:	NULL
structure	NULL
,	NULL
function	NULL
,	NULL
and	NULL
regulation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:28495-28498	NULL
.	NULL

Newton	NULL
,	NULL
A.	NULL
C.	NULL
1997	NULL
.	NULL

Regulation	NULL
of	NULL
protein	NULL
kinase	NULL
C.	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

9:161-167	NULL
.	NULL

Nirula	NULL
,	NULL
A.	NULL
,	NULL
D.	NULL
J.	NULL
Moore	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1997	NULL
.	NULL

Constitutive	NULL
binding	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
enhancer	NULL
binding	NULL
factor	NULL
to	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:7736-7745	NULL
.	NULL

Nobes	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Hall	NULL
.	NULL

1995	NULL
.	NULL

Rho	NULL
,	NULL
rac	NULL
,	NULL
and	NULL
cdc42	NULL
GTPases	NULL
regulate	NULL
the	NULL
assembly	NULL
of	NULL
multimolecular	NULL
focal	NULL
complexes	NULL
associated	NULL
with	NULL
actin	NULL
stress	NULL
fibers	NULL
,	NULL
lamellipodia	NULL
,	NULL
and	NULL
filopodia	NULL
.	NULL

Cell	NULL
81:53-62	NULL
.	NULL

Nobes	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
P.	NULL
Hawkins	NULL
,	NULL
L.	NULL
Stephens	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Hall	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
small	NULL
GTP-binding	NULL
proteins	NULL
tho	NULL
and	NULL
rac	NULL
by	NULL
growth	NULL
factor	NULL
receptors	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Sci	NULL
.	NULL

108:225-233	NULL
.	NULL

Nonaka	NULL
,	NULL
H.	NULL
,	NULL
K.	NULL
Tanaka	NULL
,	NULL
H.	NULL
Hirano	NULL
,	NULL
T.	NULL
Fujiwara	NULL
,	NULL
H.	NULL
Kohno	NULL
,	NULL
M.	NULL
Umikawa	NULL
,	NULL
A.	NULL
Mino	NULL
,	NULL
and	NULL
Y.	NULL
Takai	NULL
,	NULL
1995	NULL
.	NULL

A	NULL
downstream	NULL
target	NULL
of	NULL
Rho1	NULL
small	NULL
GTP-binding	NULL
protein	NULL
is	NULL
Pkcl	NULL
,	NULL
a	NULL
homolog	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
,	NULL
which	NULL
leads	NULL
to	NULL
activation	NULL
of	NULL
the	NULL
Map	NULL
kinase	NULL
cascade	NULL
in	NULL
Saccharomyces	NULL
cerevisiae	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:5931-5938	NULL
.	NULL

Olson	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
A.	NULL
Ashworth	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Hall	NULL
.	NULL

1995	NULL
.	NULL

An	NULL
essential	NULL
role	NULL
for	NULL
Rho	NULL
,	NULL
Rac	NULL
,	NULL
and	NULL
Cdc42	NULL
GTPases	NULL
in	NULL
cell	NULL
cycle	NULL
progression	NULL
through	NULL
G1	NULL
.	NULL

Science	NULL
269:1270-1272	NULL
.	NULL

Pasteris	NULL
,	NULL
N.	NULL
G.	NULL
,	NULL
A.	NULL
Cadle	NULL
,	NULL
L.	NULL
J.	NULL
Logie	NULL
,	NULL
M.	NULL
E.	NULL
Porteous	NULL
,	NULL
C.	NULL
E.	NULL
Schwartz	NULL
,	NULL
R.	NULL
E.	NULL
Stevenson	NULL
,	NULL
T.	NULL
W.	NULL
Glover	NULL
,	NULL
R.	NULL
S.	NULL
Wilroy	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
Gorski	NULL
.	NULL

1994	NULL
.	NULL

Isolation	NULL
and	NULL
characterization	NULL
of	NULL
the	NULL
faciogenital	NULL
dysplasia	NULL
(	NULL
Aarskog-Scott	NULL
syndrome	NULL
)	NULL
gene	NULL
:	NULL
a	NULL
putative	NULL
Rho/Rac	NULL
guanine	NULL
nucleotide	NULL
exchange	NULL
factor	NULL
.	NULL

Cell	NULL
79:669-678	NULL
.	NULL

Qiu	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
J.	NULL
Chen	NULL
,	NULL
F.	NULL
McCormick	NULL
,	NULL
and	NULL
M.	NULL
Symons	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
role	NULL
for	NULL
Rho	NULL
in	NULL
Ras	NULL
transformation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:11781-11785	NULL
.	NULL

Ridley	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
H.	NULL
F.	NULL
Paterson	NULL
,	NULL
C.	NULL
L.	NULL
Johnston	NULL
,	NULL
D.	NULL
Diekmann	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Hall	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
small	NULL
GTP-binding	NULL
protein	NULL
rac	NULL
regulates	NULL
growth	NULL
factor-induced	NULL
membrane	NULL
ruffling	NULL
.	NULL

Cell	NULL
70:401-410	NULL
.	NULL

Rho	NULL
REGULATES	NULL
AP-1	NULL
TRANSCRIPTIONAL	NULL
ACTIVATION	NULL
42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

4993	NULL
Rooney	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Y.	NULL
L.	NULL
Sun	NULL
,	NULL
L.	NULL
H.	NULL
Glimcher	NULL
,	NULL
and	NULL
T.	NULL
Hoey	NULL
.	NULL

1995	NULL
.	NULL

Novel	NULL
NFAT	NULL
sites	NULL
that	NULL
mediate	NULL
activation	NULL
of	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
T-cell	NULL
receptor	NULL
stimulation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:6299-6310	NULL
.	NULL

Sasaki	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
Kato	NULL
,	NULL
and	NULL
Y.	NULL
Takai	NULL
,	NULL
1993	NULL
.	NULL

Consequences	NULL
of	NULL
weak	NULL
interaction	NULL
of	NULL
tho	NULL
GDI	NULL
with	NULL
the	NULL
GTP-bound	NULL
forms	NULL
of	NULL
rho	NULL
p21	NULL
and	NULL
rac	NULL
p21	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:23959-23963	NULL
.	NULL

Scheffzek	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
R.	NULL
Abmadian	NULL
,	NULL
W.	NULL
Kabsch	NULL
,	NULL
L.	NULL
Wiesmuller	NULL
,	NULL
A.	NULL
Lautwein	NULL
,	NULL
F.	NULL
Schmitz	NULL
,	NULL
and	NULL
A.	NULL
Wittinghofer	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
Ras-RasGAP	NULL
complex	NULL
:	NULL
structural	NULL
basis	NULL
for	NULL
GTPase	NULL
activation	NULL
and	NULL
its	NULL
loss	NULL
in	NULL
oncogenic	NULL
Ras	NULL
mutants	NULL
.	NULL

Science	NULL
277:333-338	NULL
.	NULL

Settleman	NULL
,	NULL
J.	NULL
,	NULL
V.	NULL
Narasimhan	NULL
,	NULL
L.	NULL
C.	NULL
Foster	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Weinberg	NULL
.	NULL

1992	NULL
.	NULL

Molecular	NULL
cloning	NULL
of	NULL
cDNAs	NULL
encoding	NULL
the	NULL
GAP-associated	NULL
protein	NULL
p190	NULL
;	NULL
implications	NULL
for	NULL
a	NULL
signaling	NULL
pathway	NULL
from	NULL
ras	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

Cell	NULL
69:539-549	NULL
.	NULL

Takaishi	NULL
,	NULL
K.	NULL
,	NULL
A.	NULL
Kikuchi	NULL
,	NULL
S.	NULL
Kuroda	NULL
,	NULL
K.	NULL
Kotani	NULL
,	NULL
T.	NULL
Sasaki	NULL
,	NULL
and	NULL
Y.	NULL
Takai	NULL
.	NULL

1993	NULL
.	NULL

Involvement	NULL
of	NULL
rho	NULL
p21	NULL
and	NULL
its	NULL
inhibitory	NULL
GDP/GTP	NULL
exchange	NULL
protein	NULL
(	NULL
tho	NULL
GDT	NULL
)	NULL
in	NULL
cell	NULL
motility	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:72-79	NULL
.	NULL

Tapon	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Hall	NULL
.	NULL

1997	NULL
.	NULL

Rho	NULL
,	NULL
Rac	NULL
and	NULL
Cdc42	NULL
GTPases	NULL
regulate	NULL
the	NULL
organization	NULL
of	NULL
the	NULL
actin	NULL
cytoskeleton	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

9:86-92	NULL
.	NULL

Tsutsumi	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Kubo	NULL
,	NULL
H.	NULL
Fujii	NULL
,	NULL
J.	NULL
Freire-Moar	NULL
,	NULL
C.	NULL
W.	NULL
Turck	NULL
,	NULL
and	NULL
J.	NULL
T.	NULL
Ransom	NULL
.	NULL

1993	NULL
.	NULL

Regulation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
isoform	NULL
proteins	NULL
in	NULL
phorbol	NULL
ester-stimulated	NULL
Jurkat	NULL
T	NULL
lymphoma	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

150:1746-1754	NULL
.	NULL

Ueda	NULL
,	NULL
E.	NULL
,	NULL
S.	NULL
Ohno	NULL
,	NULL
T.	NULL
Kuroki	NULL
,	NULL
E.	NULL
Livneh	NULL
,	NULL
K.	NULL
Yamada	NULL
,	NULL
K.	NULL
Yamanishi	NULL
,	NULL
and	NULL
H.	NULL
Yasuno	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
eta	NULL
isoform	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
mediates	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
transglutaminase	NULL
1	NULL
gene	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:9790-9794	NULL
.	NULL

Verschueren	NULL
,	NULL
H.	NULL
,	NULL
P.	NULL
D.	NULL
Baetselier	NULL
,	NULL
J.	NULL
D.	NULL
Brackeleer	NULL
,	NULL
J.	NULL
Dewit	NULL
,	NULL
K.	NULL
Aktories	NULL
,	NULL
and	NULL
I	NULL
.	NULL

Just	NULL
.	NULL

ADP-ribosylation	NULL
of	NULL
Rho-proteins	NULL
with	NULL
botulinum	NULL
C3	NULL
exoenzyme	NULL
inhibits	NULL
invasion	NULL
and	NULL
shape	NULL
changes	NULL
of	NULL
T-lymphoma	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

73:182-187	NULL
.	NULL

Ward	NULL
,	NULL
S.	NULL
G.	NULL
1996	NULL
.	NULL

CD28	NULL
:	NULL
a	NULL
signalling	NULL
perspective	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

318:361-377	NULL
.	NULL

Williams	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
M.	NULL
Woodrow	NULL
,	NULL
D.	NULL
A.	NULL
Cantrell	NULL
,	NULL
and	NULL
E.	NULL
J.	NULL
Murray	NULL
.	NULL

1995	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
is	NULL
not	NULL
a	NULL
downstream	NULL
effector	NULL
of	NULL
p21ras	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25:42-47	NULL
.	NULL

Yokoyama	NULL
,	NULL
K.	NULL
,	NULL
K.	NULL
Zi	NULL
man	NULL
,	NULL
J.	NULL
Scholten	NULL
,	NULL
and	NULL
M.	NULL
H.	NULL
Gelb	NULL
.	NULL

1997	NULL
.	NULL

Differential	NULL
prenyl	NULL
pyrophosphate	NULL
binding	NULL
to	NULL
mammalian	NULL
protein	NULL
geranylgeranyl-transferase-I	NULL
and	NULL
protein	NULL
farnesyltransferase	NULL
and	NULL
its	NULL
consequence	NULL
on	NULL
the	NULL
specificity	NULL
of	NULL
protein	NULL
prenylation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:3944-3952	NULL
.	NULL

Zhang	NULL
,	NULL
F.	NULL
L.	NULL
,	NULL
P.	NULL
Kirschmeier	NULL
,	NULL
D.	NULL
Carr	NULL
,	NULL
L.	NULL
James	NULL
,	NULL
R.	NULL
W.	NULL
Bond	NULL
,	NULL
L.	NULL
Wang	NULL
,	NULL
R.	NULL
Patton	NULL
,	NULL
W.	NULL
T.	NULL
Windsor	NULL
,	NULL
R.	NULL
Syto	NULL
,	NULL
R.	NULL
Zhang	NULL
,	NULL
and	NULL
W.	NULL
R.	NULL
Bishop	NULL
.	NULL

1997	NULL
.	NULL

Characterization	NULL
of	NULL
Ha-ras	NULL
,	NULL
N-ras	NULL
,	NULL
Ki-Ras4A	NULL
,	NULL
and	NULL
Ki-Ras4B	NULL
as	NULL
in	NULL
vitro	NULL
substrates	NULL
for	NULL
farnesyl	NULL
protein	NULL
transferase	NULL
and	NULL
geranylgeranyl	NULL
protein	NULL
transferase	NULL
type	NULL
I.	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:10232-10239	NULL
.	NULL

